Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› EU
Clinical trial register · European Union · CTIS

EU Clinical Trials Tracker

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2557 most recently authorised of 12561 total CTIS records — a stated recency window, not the full historical archive. Synced 06 Oct 2026, 03:17 UTC
2557
Shown in this register
most recently authorised
12,561
Total on CTIS
full historical archive
776
Phase III
within the shown window
Top member states
Spain 1059 France 917 Germany 897 Italy 756 Poland 605 Netherlands 555
Narrow the register
Phase
Phase I 573 Phase I/II 216 Phase II 728 Phase III 776 Phase IV 264
Lead sponsor
AstraZeneca AB 66 Merck Sharp & Dohme LLC 50 Pfizer Inc. 48 Assistance Publique Hopitaux De Paris 48 Novartis Pharma AG 43
Member state
Spain 1059 France 917 Germany 897 Italy 756 Poland 605 Netherlands 555 Belgium 451 Czechia 340
All 28 states

Trials in this register

2557 of 2557 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase I/II
First-in-human study of ATX-898 as monotherapy and in combination with other anti-neoplastic agents, in participants with advanced solid tumors
2026-526514-85-00Advanced solid tumors
DrugsAbemaciclib·Ribociclib·Fulvestrant
Antares Therapeutics Inc.
Neoplasms
France
05/10/2026
Phase III
A Randomized, Double-Blind, Placebo-controlled, Safety and Efficacy Study of VI-0106 (Extended-release Tacrolimus) in Subjects with PAH and Functional Limitations Despite Optimized Therapy with Available PAH Medications
2025-524596-24-00Pulmonary Arterial Hypertension (PAH)
DrugTacrolimus
Vivus B.V., Vivus LLC
Respiratory Tract Diseases
France
05/10/2026
Phase I
A study to test how well different doses of BI 3821001 are tolerated by healthy people
2026-526877-41-00Healthy volunteer trial
Boehringer Ingelheim International GmbH
Not possible to specify
Germany
05/10/2026
Phase III
A Phase III Randomized, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants with Type 2 Diabetes Mellitus and Obesity or Overweight
2025-524616-11-00Obesity or overweight Diabetes Mellitus, Type 2
DrugLenbelintide
AstraZeneca AB
Nutritional and Metabolic Diseases
Slovakia
05/10/2026
Phase III
A Phase 3, Parallel, Randomized, Modified Double-Blind, Active-Controlled, Multi-Arm Study to Assess the Safety and Immunogenicity of a Combination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Recombinant Spike and High-Dose Inactivated Influenza Vaccine with Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older
2026-526221-18-00COVID-19, Influenza
DrugNaCl
Sanofi Vaccines US Inc.
Virus Diseases
Belgium
05/10/2026
Phase II
A Phase 2, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of ARGX-121 SC in Adult Participants With Primary IgA Nephropathy
2026-525638-43-00Immunoglobulin A nephropathy (IgAN)
Argenx
Not possible to specify
Belgium
05/10/2026
Phase III
A Phase III Randomised, Double-Blind, Factorial Design Study to Assess the Effect of Fixed Dose Combination Laroprovstat/Rosuvastatin compared with Laroprovstat, Rosuvastatin, and Placebo on Low-Density Lipoprotein Cholesterol in Lipid-Lowering Treatment-Naïve Patients
2026-525642-30-00Hypercholesterolaemia
DrugsAZD0780·Rosuvastatin
AstraZeneca AB
Nutritional and Metabolic Diseases
Denmark
05/10/2026
Phase II
A phase 2 study to assess efficacy of induction Enfortumab Vedotin plus Pembrolizumab using a response-adapted approach to spare the bladder: FIDELIO
2026-525965-29-00Adult patients with cT2-4aN0-1 urothelial bladder cancer, w…
DrugsEnfortumab Vedotin·Pembrolizumab
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Neoplasms
Netherlands
05/10/2026
Phase III
A Phase 3b/4, Multicenter, Parallel-Group, Double-Blind, Placebo-Controlled, Two-Arm, Long-Term Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium on Clinical Outcomes in Participants with Primary Biliary Cholangitis (PBC)
2025-524067-20-00Primary Biliary Cholangitis (PBC)
DrugSaroglitazar Magnesium
Zydus Therapeutics Inc.
Digestive System Diseases
Greece, Netherlands, Spain
05/10/2026
Phase III
A randomized, double-blind, placebo-controlled, 2-arm multicenter Phase III study to assess the efficacy and safety of ianalumab in participants with Sjogren's disease with high symptom burden (THALASSA)
2025-522271-29-00Sjögren's disease
DrugsTenofovir Alafenamide·Entecavir·Ianalumab
Novartis Pharma AG
Immune System Diseases
Slovakia, France, Netherlands
05/10/2026
Phase III
Prediction and Prevention of Bloodstream Infections After Kidney Transplantation - the PREDICT Study
2026-527337-63-00Bacterial urinary tract infections and bloodstream infectio…
DrugPivmecillinam
Region Hovedstaden
Bacterial Infections and Mycoses
Denmark
05/10/2026
Phase IV
Proof-of-Concept Evaluation of Immunological Assays Using Human Blood and Urine Samples after Vaccination with StroVac
2026-527508-25-00Urinary Tract Infection
Strathmann GmbH & Co. KG
Diagnosis
Germany
05/10/2026
Phase II
LIGHTBEAM-U01 Substudy 01E: A Phase 2 Substudy to Evaluate the Safety and Efficacy of Belzutifan in Participants With Solid Tumors
2025-524515-37-00Neoplasm malignant
DrugBelzutifan
Merck Sharp & Dohme LLC
Neoplasms
Belgium, Denmark
05/10/2026
Phase IV
Tapering optimisation with placebo-based mechanisms in rheumatoid arthritis: the TOP-RA trial
2025-524593-42-00Rheumatoid Arthritis
DrugsCertolizumab Pegol·Abatacept·Sarilumab·Etanercept
Universiteit Leiden
Musculoskeletal Diseases
Netherlands
05/10/2026
Phase I/II
A Phase Ib/II, open-label, safety and tolerability trial of obrixtamig in combination with ZL-1310 in patients with poorly differentiated NEC
2026-525634-27-00Extrapulmonary neuroendocrine carcinoma of large cell histo…
DrugsZL-1310·Obrixtamig·Tocilizumab·Atezolizumab
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Neoplasms
France, Belgium, Netherlands
05/10/2026
Phase III
Multicenter and randomised study on atrial fibrillation prevention after cardiac surgery with a 3-way comparison between standard of care, posterior pericardiotomy and a treatment bundle (colchicine, amiodarone and posterior pericardiotomy) (PREV-AF)
2025-523209-14-00Atrial fibrillation
DrugsAmiodarone Hydrochloride·Bisoprolol·Heparin
Clinique Saint Augustin
Cardiovascular Diseases
France
02/10/2026
Phase III
A Randomized, Double-Blind, Phase II Investigator Initiated Trial of Upadacitinib and Short Glucocorticoid Tapering in Giant Cell Arteritis
2025-523199-22-00Giant Cell Arteritis
DrugUpadacitinib
Rheinische Friedrich-Wilhelms-Universitaet Bonn
Immune System Diseases
Germany
02/10/2026
Phase III
Comparing two common administration styles of racemic ketamine with a TCI model for perioperative analgesia in patients undergoing spinal fusion surgery: A prospective, randomized, single center trial with three parallel groups
2026-527990-12-00spinal fusion surgery
DrugKetamine
CHU Saint Pierre
Musculoskeletal Diseases
Belgium
02/10/2026
Phase III
Impact of Semaglutide in Liver Transplant Candidates with Obesity (SOMAL Study): A Prospective Randomized Study.
2026-526953-32-00Arterial hypertension, Type 2 diabetes mellitus, Obesity, D…
DrugSemaglutide
Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia
Surgical Procedures, Operative
Spain
02/10/2026
Phase IV
OPTIMIZING THE TREATMENT WITH MEROPENEM FOR FOREIGN-BODY BONE AND JOINT INFECTIONS: PLASMA/BONE PHARMACOKINETICS WITH CONTINUOUS VS INTERMITTENT INFUSION
2026-527210-22-00BONE AND JOINT INFECTIONS
DrugMeropenem
Consorci Mar Parc De Salut De Barcelona
Bacterial Infections and Mycoses
Spain
02/10/2026
Phase I
A research study to evaluate the safety of NNC9836-0001 when given to healthy participants and participants with type 2 diabetes
2026-525819-14-00Type 2 diabetes
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Germany
02/10/2026
Phase IV
PRIMO : Precision immunosuppressive drug monitoring in liver transplantation: a randomized control trial
2025-523563-38-00Immunosuppressive treatment in the context of liver transpl…
DrugTacrolimus
Centre Hospitalier Universitaire De Rennes
Digestive System Diseases
France
01/10/2026
Phase I
An open-label, randomized, single-dose, two-way cross-over study to assess the tolerability and pharmacokinetics of NRT001 nicotine buccal film compared with an oromucosal nicotine spray in adult occasional nicotine users
2024-518034-91-00Nicotine Replacement Therapy
OPES Corporation Oy
Not possible to specify
Finland
01/10/2026
Phase III
A Phase III, Multicenter, Randomized, Controlled, Double-Blind Study Comparing the Efficacy and Safety of High-Dose (4%) versus Standard (2%) Lidocaine Gel for Local Anesthesia in Transurethral Procedures
2026-526288-40-00Placement or exchange of double-J (DJ) ureteral stent
DrugLidocaine
Farco-Pharma GmbH
Female Urogenital Diseases and Pregnancy Complications
Germany
01/10/2026
Phase IV
A long-term prospective monitoring study of all patients with Pompe Disease. Evaluating natural history, treatment response, disease markers and novel outcome measures.
2024-520365-31-01Pompe disease / glycogenosis type II / acid maltase deficie…
DrugsAlglucosidase alfa·Cipaglucosidase alfa·Miglustat·Avalglucosidase alfa
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Nutritional and Metabolic Diseases
Netherlands
01/10/2026
Phase IV
Crohn’s disease Longitudinal Evaluation of Anti-fibrotic Response to UPadacitinib
2025-523038-16-00Crohn’s disease with ileal stricturing complication
DrugUpadacitinib
UZ Leuven
Digestive System Diseases
Germany, Belgium
01/10/2026
Phase III
A prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial to evaluate the efficacy and safety of subcutaneous immunotherapy with polymerized grass pollen extracts in patients with grass pollen–induced allergic rhinitis/rhinoconjunctivitis with or without mild-to-moderate asthma
2026-526100-73-00Grass pollen induced moderate-to-severe allergic rhinitis o…
Inmunotek S.L.
Immune System Diseases
Poland, Spain
01/10/2026
Phase III
C3671017 A PHASE 3 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS VACCINE IN CHILDREN AT HIGH RISK OF RSV DISEASE
2026-525797-19-00Prevention of lower respiratory tract disease caused by res…
DrugVaxzevria
Pfizer Inc.
Respiratory Tract Diseases
Spain, Poland
01/10/2026
Phase I
EVALUATION OF PHARMACOKINETICS, PHARMACODYNAMICS, AND TOLERABILITY OF A NOVEL NICOTINE THERAPY IN HEALTHY SMOKERS
2026-527188-14-00nicotine dependence
Flik Therapeutics Inc.
Nervous System Diseases
Poland
01/10/2026
Phase II
Breast density reduction with linzagolix or bilastine in premenopausal women at high risk of breast cancer: a phase II clinical trial.
2026-525672-26-01Increased risk of breast cancer
Consorci Mar Parc De Salut De Barcelona
Neoplasms
Spain
01/10/2026
Phase I/II
A phase 1/2 clinical study evaluating MDX2003 in participants with relapsed, progressive, or refractory B-cell malignancies
2026-526661-26-00Relapsed/Refractory B-cell Malignancies
Modex Therapeutics Inc.
Hemic and Lymphatic Diseases
Spain, Italy
01/10/2026
Phase II
Hex-SUB1-IPC 2025-067 - PROOF OF CONCEPT: FEASIBILITY OF PHOTODYNAMIC DIAGNOSIS IN BLADDER CANCER PATIENTS WITH SUB-ONE-HOUR INSTILLATION TIME OF HEXAMINOLEVULINATE (HEXVIX®)
2026-526917-27-00primary or recurrent confirmed papillary bladder cancer (BC)
DrugHexvix
Institut Paoli Calmettes
Neoplasms
France
30/09/2026
Phase IV
Pharmacokinetic study of pembrolizumab and its impact on immunity and the tumor microenvironment, which may explain the efficacy of post-immunotherapy chemotherapy - CPI
2026-526866-26-00Non-small cell lung cancer (NSCLC) and Head and neck squamo…
DrugsCetuximab·Gemcitabine·Paclitaxel·Bevacizumab
Centre Antoine Lacassagne
Neoplasms
France
30/09/2026
Phase III
iSGLT2 in permanent atrial fibrillation, heart failure with preserved ejection fraction and intermediate NT-proBNP values: randomized clinical trial
2026-525968-18-00Heart failure, Atrial Fibrillation
Institut D Investigacio Sanitaria Pere Virgili
Cardiovascular Diseases
Spain
30/09/2026
Phase I
Human study to evaluate how NDI-225673 works and to determine an appropriate dose
2026-527578-35-00Inflammatory bowel disease
Nimbus Salacia Inc.
Immune System Diseases
Netherlands
30/09/2026
Phase I
A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 are Tolerated and Act in the Body in Healthy Adults or Adults With Mild-to-Moderate Asthma
2026-526260-21-00Atopic dermatitis, asthma and other type 2 inflammatory dis…
Pfizer Inc.
Immune System Diseases
Belgium
30/09/2026
Phase I
Study of safety and tolerability of BCA101 monotherapy and in combination therapy in patients with EGFR-driven advanced solid tumors
2026-526745-99-00Advanced solid tumors
Bicara Therapeutics Inc.
Neoplasms
Spain, France
30/09/2026
Phase II
SEMAGONA: A randomized four-arm parallel group double-blind double dummy 52-week clinical trial comparing the effects of s.c. Semaglutide 2.4 mg once-weekly, i.m. testosterone undecanoate 1,000 mg every 13th week, combination of s.c. Semaglutide 2.4 mg once-weekly and i.m. testosterone undecanoate 1,000 mg every 13th week, and placebo on body composition and hypogonadal symptoms in men with obesity-associated functional hypogonadism
2026-527373-11-00Functional hypogonadism
DrugsNebido·Semaglutide
Region Hovedstaden
Hormonal diseases
Denmark
30/09/2026
Phase III
A multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of a subcutaneous allergoid preparation of house dust mite allergens (Dermatophagoides pteronyssinus / Dermatophagoides farinae) in patients with moderate to severe allergic rhinitis/rhinoconjunctivitis with or without controlled allergic asthma.
2026-526213-28-00House dust mite allergy
DrugsDesloratadine·Mometasone furoate
Allergopharma GmbH & Co. KG
Immune System Diseases
Spain
30/09/2026
Phase I
A PHASE I, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND COHORT EXPANSION STUDY OF MINT91 IN COMBINATION WITH OTHER ANTI-CANCER DRUGS IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
2025-521544-38-00LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
Chugai Pharmaceutical Co. Ltd.
Neoplasms
France
30/09/2026
Phase II
PHOENIX - ECP: A Phase 2, Randomized, Controlled, Open-label, Multicenter Study to Evaluate the Efficacy and Safety/Tolerability of Extracorporeal Photopheresis (ECP) Versus Best Available Therapy (BAT) for the Treatment of Immune-related Colitis and/or Hepatitis with Inadequate Response to Corticosteroids in Participants with Unresectable or Metastatic Melanoma Treated with Immune Checkpoint Inhibitors (ICI)
2026-526261-14-00Immune-related Colitis or Hepatitis with Inadequate Respons…
DrugsAzathioprine·Vedolizumab·Infliximab
Therakos Europe Limited
Neoplasms
Austria, Spain, Italy, Germany, Netherlands
30/09/2026
Phase I
A clinical trial of MK-3586 in healthy participants (MK-3586-001)
2026-527250-39-00Rheumatoid arthritis
Merck Sharp & Dohme LLC
Immune System Diseases
Belgium
30/09/2026
Phase II
Safety and Tolerability of systemic administration of metformin in patients with Idiopathic Pulmonary Fibrosis (IPF): A randomized, placebo-controlled, double-blind, phase II proof-of-concept study (Met_for_IPF)
2025-523341-10-00Idiopathic pulmonary fibrosis
Philipps-Universitaet Marburg
Respiratory Tract Diseases
Germany
30/09/2026
Phase I/II
A Phase 1/2, First-in-Human, Multicenter, Ascending Single-Dose and Multi-Dose Study to Assess the Safety of DIAG723, a Novel Bispecific ALK-1 and BMPRII Agonist Antibody in Adult Patients with Hereditary Hemorrhagic Telangiectasia (DIAMOND trial)
2026-526271-29-00Hereditary Hemorrhagic Telangiectasia (HHT)
Diagonal Therapeutics Inc.
Hemic and Lymphatic Diseases
Germany
30/09/2026
Phase I
A Study of PRO-203 in Healthy Volunteers and Participants with Systemic Sclerosis
2026-526659-70-00systemic sclerosis
Prolium Bioscience Inc.
Immune System Diseases
Germany
30/09/2026
Phase I/II
A Phase 1/2, Multicenter, First-in-Human, Dose Escalation and Expansion Study Evaluating CHM-029, as Monotherapy and in Combination with Standard Therapies in Participants with Relapsed or Refractory, or Newly Diagnosed Acute Myeloid Leukemia (AML) with NPM1 Mutations, KMT2A or NUP98 Rearrangements
2026-526409-14-00Acute Myeloid Leukemia
DrugsPosaconazole·Daunorubicin·Cytarabine·Azacitidine
Charm Therapeutics Limited
Neoplasms
France, Germany, Spain, Poland, Netherlands
30/09/2026
Phase I
An open-label, DDI study to investigate the effects of duvakitug on the PK of selected cytochrome P450 substrates
2026-525939-17-00Colitis ulcerative, Crohn's disease
Sanofi-Aventis Recherche & Developpement
Digestive System Diseases
Germany
30/09/2026
Phase I
A phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
2024-518348-19-00Advanced bladder cancer, Advanced Breast cancer (HER2+, HR+…
Novartis Pharma AG
Neoplasms
France, Italy, Spain, Portugal, Germany, Belgium
29/09/2026
Phase III
A Phase 3, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Olatorepatide, a GLP-1/GIP Receptor Agonist, in Participants Living with Overweight or Obesity without Diabetes (RISE-1)
2025-524861-26-00Overweight or Obesity Without Diabetes.
DrugOlatorepatide
Regeneron Pharmaceuticals Inc.
Nutritional and Metabolic Diseases
Poland, Hungary, Germany, Spain
29/09/2026
Phase III
A Phase 3, Randomized, DoubleBlind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial Hypertension (PALM-PAH)
2026-525265-48-00Pulmonary Arterial Hypertension
DrugTreprostinil Palmitil
Insmed Inc.
Respiratory Tract Diseases
Germany, Hungary, Belgium, France, Italy, Sweden, Austria, Lithuania, Greece
29/09/2026
Phase I
Basket trial for B-cEll driven severe auToimmunE and aLoimmune diseases (chronic Graft vErsUs host diseaSe) treated with anti-CD19 CAR T-cell thErapy
2025-522821-37-00Dermatomyositis/Polymyositis (DM/PM), Systemic Sclerosis (S…
Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico, Ospedale Pediatrico Bambino Gesu
Skin and Connective Tissue Diseases
Italy
29/09/2026
Phase III
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer’s Disease
2025-524314-29-00Cognitively Unimpaired Individuals at Risk for Progression …
DrugTrontinemab
F. Hoffmann-La Roche AG
Nervous System Diseases
Spain, Denmark
29/09/2026
Phase III
A Phase 3, Randomized, Multicenter, Double-blind Study to Assess Stroke and Systemic Embolism Prevention with REGN7508, a Monoclonal Antibody Against Factor XI, Versus Apixaban in Participants with Atrial Fibrillation (ROXI-EVEREST)
2025-521617-97-00Atrial Fibrillation (AF)
DrugsCenvacibart·Apixaban
Regeneron Pharmaceuticals Inc.
Cardiovascular Diseases
Germany, Italy, Czechia, Austria, Spain, Belgium, Netherlands, Poland, Sweden, Greece, Latvia, Hungary, Bulgaria, Romania
29/09/2026
Phase II
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Tolerability, and Efficacy of MZE782 in Adults with Phenylketonuria (PKU)
2026-525622-37-01Phenylketonuria
Maze Therapeutics Inc.
Nutritional and Metabolic Diseases
Germany, France, Netherlands
29/09/2026
Phase III
A Master Protocol for a Phase 3, Randomized, Multicenter, Double-blind Study to Assess Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, versus Placebo in Participants with Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable (ROXI-INCLINE)
2025-521618-25-00Atrial Fibrillation (AF)
DrugsAmrecibart·Cenvacibart
Regeneron Pharmaceuticals Inc.
Cardiovascular Diseases
Spain, Bulgaria, Hungary, Poland, Romania, Sweden, Germany, Italy, Latvia, Netherlands, Portugal
29/09/2026
Phase II
A Randomized, Double-Blind, Placebo-controlled, Parallel Arm, 52-week Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Two Doses of EXPD-101 in Participants with COPD
2026-525216-34-00Chronic Obstructive Pulmonary Disease (COPD) exacerbations
Expedition Therapeutics Inc.
Respiratory Tract Diseases
Italy, Germany, Spain, Poland, Czechia, Romania, Hungary, Denmark, Bulgaria
29/09/2026
Phase I
A phase I, open-label, dose-escalation, safety, pharmacokinetic/-dynamic and clinical activity study of p38α inhibitor Skepinone-L to enhance therapeutic efficacy of Sorafenib in advanced hepatocellular carcinomas of non-viral origin
2024-511516-24-00Hepatocellular Carcinoma (HCC)
Universitaetsklinikum Tuebingen AöR
Immune System Diseases
Germany
29/09/2026
Phase III
A Master Protocol for a Phase 3, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, in Participants with Recent Lower Extremity Revascularization for Symptomatic Peripheral Artery Disease (ROXI-PALISADE)
2025-522954-37-00Peripheral Artery Disease
DrugsAmrecibart·Cenvacibart·Rivaroxaban
Regeneron Pharmaceuticals Inc.
Hemic and Lymphatic Diseases
Spain, Slovakia, Hungary, Czechia, Romania, Estonia, Austria, France, Belgium, Sweden, Italy, Latvia, Poland, Bulgaria, Greece, Germany, Denmark, Lithuania, Netherlands
29/09/2026
Phase II
Effects of a CB1 Receptor Antagonist/Inverse Agonist (Rimonabant) on the Improvement of Cognitive Impairment in Patients with Post-COVID-19 Syndrome (RIMOCOVID-1)
2023-507870-42-00Post-COVID-19 syndrome
Sinfatin S.L.
Virus Diseases
Spain
28/09/2026
Phase III
Assessing the efficacy of vasculoprotective dapagliflozin treatment in septic shock patients with microcirculatory dysfunction (GLIFLOSHOCK)
2025-524820-23-00Septic chock
DrugDapagliflozin
Les Hopitaux Universitaires De Strasbourg
Not possible to specify
France
28/09/2026
Phase III
A prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial to evaluate the efficacy and safety of subcutaneous immunotherapy with polymerized olive pollen (Olea europaea) extracts in patients with olive pollen–induced allergic rhinitis/rhinoconjunctivitis with or without mild-to-moderate asthma
2026-526390-41-00Moderate-to-severe allergic rhinitis or rhinoconjunctivitis…
Inmunotek S.L.
Immune System Diseases
Spain
28/09/2026
Phase III
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease
2026-526778-18-00Anemia in subjects with sickle cell disease (SCD)
DrugMitapivat
Agios Pharmaceuticals Inc.
Hemic and Lymphatic Diseases
Italy, France, Belgium, Ireland
28/09/2026
Phase I
A prospective, open-label, single-arm, multicenter pharmacokinetic study evaluating the placental transfer of dapirolizumab pegol to the infant(s) from pregnant study participants with active systemic lupus erythematosus who are administered dapirolizumab pegol
2025-524595-37-00Systemic lupus erythematosus (SLE)
DrugsDiphenhydramine·Epinephrine·Paracetamol
UCB Biopharma
Immune system processes
Greece, Italy, Netherlands, Austria, Belgium, Sweden, Spain, Denmark, Germany
28/09/2026
Phase IV
Using GLP-1 to prevent Post-Transplantation Diabetes Mellitus
2026-525910-77-00Post-transplantation Diabetes Mellitus
DrugsGlucagon·Semaglutide
Radboud universitair medisch centrum Stichting
Hormonal diseases
Netherlands
28/09/2026
Phase I
[¹⁸F]MC225 PET Analysis of Blood–Brain Barrier Function in Glioblastomas
2026-526106-32-00Glioblastoma
Universitair Medisch Centrum Groningen
Nervous System Diseases
Netherlands
28/09/2026
Phase III
A Multicenter, Phase 2/3, Dose Range Finding Study to Evaluate the Efficacy and Safety of Atumelnant in Adults with ACTH-Dependent Cushing’s Syndrome (ADCS) Including an Open-Label Extension for Long-Term Assessment. (EQUILIBRIUM-ADCS)
2025-522648-42-01• ACTH-Dependent Cushing’s Syndrome. • Pituitary-dependent …
DrugsAtumelnant·Hydrocortisone
Crinetics Pharmaceuticals Inc.
Not possible to specify
Sweden, Austria, Spain, Poland, Netherlands, Italy, Germany, France
28/09/2026
Phase III
C4931004 - A Phase 3, Randomized Double-Blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Catch-Up Vaccination Regimen of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Children and Adolescents
2025-523445-10-00Pneumoccoccal Immunisation
DrugPF-07872412
Pfizer Inc.
Bacterial Infections and Mycoses
Poland, Finland
28/09/2026
Phase I
Drug-drug interaction study of midazolam and brensocatib
2026-526670-16-00Non-Cystic Fibrosis Bronchiectasis
Insmed Inc.
Respiratory Tract Diseases
Netherlands
28/09/2026
Phase III
An Open-label Extension Study to Assess the Long-term Safety and Efficacy of Danicamtiv in Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-OLE).
2026-526139-20-00Symptomatic genetic and familial dilated cardiomyopathy.
DrugDanicamtiv
Kardigan Inc.
Cardiovascular Diseases
Poland, Sweden, Belgium, France, Spain, Hungary, Denmark, Italy, Netherlands
28/09/2026
Phase I
A study to investigate safety and effectiveness of REM0045392 compared with placebo in healthy elderly participants and participants with Alzheimer’s disease
2026-527490-11-00Alzheimer's disease
reMYND
Nervous System Diseases
Denmark
28/09/2026
Phase III
A Phase 1/2/3, Open-Label, Dose Escalation, Dose Expansion, and Randomized, Controlled Study to Evaluate the Safety and Efficacy of ATSN-201 Gene Therapy in Subjects with RS1-Associated X-linked Retinoschisis (LIGHTHOUSE)
2026-525886-38-00Inherited retinal dystrophy due to dysfunction in the human…
Atsena Therapeutics Inc.
Eye Diseases
Italy, Germany, Spain, Netherlands, France, Belgium
28/09/2026
Phase III
A Phase 3 Global, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Demonstrate the Efficacy, Safety, and Tolerability of Claseprubart (DNTH103) in Patients with Generalized Myasthenia Gravis (EMERGE)
2026-525298-38-00generalized Myasthenia gravis
DrugClaseprubart
Dianthus Therapeutics Inc.
Immune System Diseases
Czechia, Portugal, Austria, Bulgaria, Germany, France, Latvia, Poland, Italy, Spain, Denmark
28/09/2026
Phase III
SHING-ID: Fractional dose shingles vaccination
2026-526934-16-00Shingles
Leids Universitair Medisch Centrum (LUMC)
Virus Diseases
Netherlands
28/09/2026
Phase II
FILOCLL017 - NEVOTAL : Nemtabrutinib in addition to Venetoclax-Obinutuzumab in chronic lymphocytic leukemia (CLL) / small lymphocytic leukemia (SLL) patients with TP53 ALterations
2026-525763-40-00Patients with previously untreated chronic lymphocytic leuk…
DrugsNemtabrutinib·Obinutuzumab·Venetoclax
French Innovative Leukemia Organization (F.I.L.O.).
Hemic and Lymphatic Diseases
France
25/09/2026
Phase I
A Study to Learn About the Study Medicine Called PF-08032562 in People with Advanced or Metastatic Solid Tumors
2025-524387-38-00metastatic/advanced breast cancer (BC) and colorectal cance…
Pfizer Inc.
Neoplasms
France, Spain
25/09/2026
Phase II
A phase 2, open-label, Multicenter, Randomized study of Trastuzumab Deruxtecan versus investigator’s choice chemotherapy in recurrent ovarian cancer that progressed on prior PARP inhibitor therapy: TROY (APGOT-OV14)
2026-527010-23-00Ovarian cancer
DrugsTrastuzumab deruxtecan·Bevacizumab
Fundacion Grupo Espanol De Investigacion En Cancer Ginecologico
Neoplasms
Spain
25/09/2026
Phase III
POst-Therapy ENhanced Thrombocyte Inhibition At Low NIHSS score (POTENTIAL) – A randomized controlled multicenter trial
2026-525681-22-00Secondary prevention after stroke
DrugsAcetylsalicylic acid·Clopidogrel
Technische Universitaet Dresden
Cardiovascular Diseases
Germany
25/09/2026
Phase I
[14C]Navlimetostat Mass Balance Study in Healthy Female Participants
2026-527504-24-00Advanced Solid Tumors
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Netherlands
24/09/2026
Phase II
RINGQUEST: Exploring Understudied Genitourinary Tumors with Sacituzumab Tirumotecan; a Single-arm, Basket, Phase II Study.
2026-526048-10-00Papillary Renal Cell Carcinoma (pRCC) Variant Histology Uro…
DrugSacituzumab tirumotecan
Alianza Multidisciplinar Para La Investigacion De Los Tumores Genitourinarios Guard
Neoplasms
Spain
24/09/2026
Phase III
A Phase II/III Multicenter, Randomized, Masked, Active Comparator-Controlled Study to Evaluate the Safety and Efficacy of Two Doses of OCUL101, an Anti-VEGF and Anti-Complement C5, Bi-specific Humanized Antibody-Like “trap” in Participants with Neovascular Age-Related Macular Degeneration with or without Geographic Atrophy – STAT Study
2026-526648-11-00Neovascular age-related macular degeneration (nAMD)
DrugAflibercept
Shenzhen Oculgen Biomedical Technology Co. Ltd.
Eye Diseases
Latvia, Poland, Czechia, Hungary
24/09/2026
Phase II
A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Efficacy and Safety of Nalbuphine Extended-Release Tablets for the Treatment of Participants with Refractory Chronic Cough
2026-526087-20-00Refractory Chronic Cough
DrugNalbuphine
Trevi Therapeutics Inc.
Respiratory Tract Diseases
Poland
24/09/2026
Phase II
A Phase 2b, Double-Blind, Placebo-Controlled, Multicenter Proof of Concept Clinical Study to Evaluate the Efficacy and Safety of ATH-063 Induction Therapy in Patients with Biologic Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)
2024-520183-33-00Active Ulcerative Colitis
Athos Therapeutics Inc.
Digestive System Diseases
Poland
24/09/2026
Phase III
A phase 3 randomized, observer-blind, controlled study to evaluate the immunogenicity, reactogenicity and safety of an mRNA-based seasonal influenza vaccine, in adults 18-64 years of age
2026-526925-17-00Influenza, Human
GlaxoSmithKline Biologicals
Virus Diseases
Belgium, Germany
24/09/2026
Phase III
A phase 3 randomized, observer-blind, controlled study to evaluate the clinical efficacy of an mRNA- based seasonal influenza vaccine in older adults ≥65 years of age
2026-526682-14-00Influenza, Human
GlaxoSmithKline Biologicals
Virus Diseases
Belgium, Germany, Finland, Spain
24/09/2026
Phase I/II
ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination with Ipilimumab or Cabozantinib in Participants with Advanced Renal Cell Carcinoma (RCC)
2026-527163-15-00Advanced Renal Cell Carcinoma
DrugsCabozantinib·Ipilimumab
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Ireland, Romania, Italy, Spain, Czechia, Finland, France, Germany
24/09/2026
Phase II
OASIS-ImmunoPET_Antibody-based PET imaging and treatment response in breast cancer treated with an antibody-drug conjugate according to current standard indications.
2025-524369-26-00Patients with histologically confirmed or radiologically do…
Unicancer
Neoplasms
Belgium
23/09/2026
Phase II
Use of the Checkpoint inhibitor DOstarlimab in the endOmetrial cancer fertility-Sparing trEatment: CHOOSE study.
2023-509535-11-00Newly diagnosed endometrial carcinomas of the MMR-deficient…
DrugDostarlimab
UZ Leuven
Neoplasms
Italy, Belgium
23/09/2026
Phase III
A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma (TROPION-Urothelial04).
2025-525030-57-00High-risk muscle invasive urothelial carcinoma (MIUC) origi…
DrugsMycophenolate Mofetil·Infliximab·Rilvegostomig·Enfortumab Vedotin
AstraZeneca AB
Neoplasms
Italy, Poland, Spain, France, Germany
23/09/2026
Phase I
A research trial in healthy participants to learn how a new formulation of JNJ‑77730614 is absorbed and processed by the body, and how well both the new formulation and the buccal delivery system (cup) are tolerated
2026-526295-22-00Healthy Participants
Janssen Cilag International
Immune System Diseases
Belgium
23/09/2026
Phase I
A clinical trial of MK-1824 in healthy participants (MK-1824-002)
2026-527518-22-00Heart failure with preserved ejection fraction
Merck Sharp & Dohme LLC
Cardiovascular Diseases
Belgium
23/09/2026
Phase II
An Open-Label Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of Vafidemstat in Adults with Phelan-McDermid Syndrome (PMS) (HOPE-2).
2026-525699-24-00Phelan McDermid Syndrome
Oryzon Genomics S.A.
Behavior and Behavior Mechanisms
Spain
23/09/2026
Phase III
LUMIOS - A Phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group trial to assess the efficacy, safety and tolerability of cenerimod in adult patients with systemic lupus erythematosus and active lupus nephritis in combination with background therapy
2025-522984-14-00Systemic lupus erythematosus and active lupus nephritis
DrugCenerimod
Viatris Innovation GmbH
Immune System Diseases
Germany, Spain, Poland, Bulgaria, Romania
23/09/2026
Phase III
J2A-MC-GZGY: A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Once-Daily Oral Orforglipron Compared With Once-Weekly Dulaglutide in Pediatric Participants 10 to Less Than 18 Years of Age With Type 2 Diabetes
2025-524811-35-00Diabetes Mellitus, Type 2
DrugsDulaglutide·Orforglipron
Eli Lilly & Co.
Nutritional and Metabolic Diseases
Italy, Spain, Belgium
22/09/2026
Phase I
A Study of Long-Term Safety, Tolerability, and Clinical Outcomes of Intrathecally Administered LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis: A Multicenter, Open-Label, Long-Term Extension of Study J6I-MC-OWAA
2026-525574-19-00Amyotrophic Lateral Sclerosis
Eli Lilly & Co.
Nervous System Diseases
Netherlands, Belgium, Germany, Spain
22/09/2026
Phase III
A Phase 3b, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lebrikizumab in Adult and Adolescent Participants with Moderate-to-Severe Face and Neck Atopic Dermatitis
2025-525133-31-00Face and Neck Atopic Dermatitis
DrugLebrikizumab
Almirall S.A.
Skin and Connective Tissue Diseases
Poland, Germany, Portugal, France, Spain, Denmark
22/09/2026
Phase I
A PHASE 1 FIRST-IN-HUMAN OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND PRELIMINARY EFFICACY OF ERAS-0015 MONOTHERAPY AND IN COMBINATION IN PATIENTS WITH ADVANCED SOLID TUMORS
2026-525794-39-00Solid Tumors
Erasca Inc.
Neoplasms
Spain
21/09/2026
Phase IV
A phase IV randomised, parallel-group, double-blinded, placebo-controlled, trial evaluating the efficacy of the tree SLIT-tablet in adolescents (12-17 years of age) with allergic rhinitis/allergic rhinoconjunctivitis induced by birch pollen using an environmental exposure unit.
2026-526861-88-00Moderate to severe allergic rhinitis/allergic rhinoconjunct…
Alk-Abello A/S
Immune System Diseases
France
21/09/2026
Phase II
A Phase 2b, Randomized, Placebo-controlled, Double-blind, Dose-ranging Trial to Assess the Efficacy and Safety of Ontunisertib in Patients with Fibrostenosing Crohn’s Disease
2026-525197-19-00Fibrostenosing Crohn’s Disease
DrugOntunisertib
Agomab Spain S.L.U.
Digestive System Diseases
France, Germany, Poland, Spain, Czechia, Denmark, Austria, Italy, Belgium, Netherlands
21/09/2026
Phase III
A Phase 3, Randomized, Double-Blind Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Participants with Obesity or Overweight
2026-525408-82-00Chronic Weight Management
DrugMaridebart cafraglutide
Amgen Inc.
Nutritional and Metabolic Diseases
Czechia, Spain, Poland, Denmark, Germany, Italy, Belgium, Finland
21/09/2026
Phase I
A phase I study to investigate the immune response and safety of the marketed rotavirus vaccin administered to adult at a higher dose than the original paediatric dose.
2026-527817-46-00Rotavirus
Universiteit Antwerpen
Virus Diseases
Belgium
21/09/2026
Phase III
A Phase 3, Randomized, Double-Blind Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Participants with Obesity or Overweight with Type 2 Diabetes Mellitus
2025-524788-19-00Chronic Weight Management
DrugMaridebart cafraglutide
Amgen Inc.
Nutritional and Metabolic Diseases
Germany, Hungary, Czechia, Italy, Poland, Bulgaria
21/09/2026
Phase III
A global phase 3 randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in children with sickle cell disease
2025-524464-38-00Sickle cell disease
Novo Nordisk A/S
Hemic and Lymphatic Diseases
France, Netherlands, Spain, Italy
21/09/2026
Phase III
A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 as an Adjunct to Incretin-based Therapies in Participants with Obesity or Overweight with at Least One Weight-Related Comorbidity With or Without Type 2 Diabetes Mellitus
2025-523295-23-00Obesity or Overweight Weight-Related Comorbidity with/witho…
DrugLenbelintide
AstraZeneca AB
Nutritional and Metabolic Diseases
Sweden, Denmark
21/09/2026
Phase III
A randomized, open-label, multicenter, Phase 3 study to investigate mocertatug rezetecan compared with chemotherapy in participants with endometrial cancer after platinum-based chemotherapy and immunotherapy
2025-523362-25-00Neoplasms, Endometrial
DrugsDoxorubicin·Paclitaxel
Glaxosmithkline Research & Development Limited
Neoplasms
Denmark, Netherlands, Italy, Spain, France, Portugal, Greece, Poland, Germany, Belgium, Norway, Czechia
21/09/2026
Phase III
A randomized, open-label, multicenter, Phase 3 study to investigate mocertatug rezetecan compared with standard of care in participants with platinum- resistant ovarian cancer.
2025-523361-25-00Ovarian Neoplasms
DrugsDoxorubicin·Gemcitabine·Paclitaxel·Bevacizumab
Glaxosmithkline Research & Development Limited
Neoplasms
Denmark, Austria, France, Sweden, Finland, Netherlands, Norway, Czechia, Belgium, Greece, Italy, Germany, Spain
21/09/2026
Phase III
A Randomized Phase 2/3 Study of Ivonescimab in Combination with Enfortumab Vedotin vs Pembrolizumab in Combination with Enfortumab Vedotin in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (HARMONi GU1)
2026-525831-17-00Locally Advanced or Metastatic Urothelial Carcinoma
DrugsEnfortumab Vedotin·Ivonescimab·Pembrolizumab
Summit Therapeutics Inc.
Neoplasms
Spain
21/09/2026
Phase I
A Phase 1, non-randomized, fixed-sequence, multiple-dose study investigating the drug drug interaction potential and QTc effects of fosmanogepix in healthy adult subjects.
2026-526076-23-00Invasive fungal infections (IFIs)
Basilea Pharmaceutica International AG Allschwil
Not possible to specify
Netherlands
21/09/2026
Phase IV
Influence of Antimicrobial Drugs on Mycophenolic acid and Tacrolimus Pharmacokinetics and the Gut Microbiome in Kidney Transplant Recipients (AXIS)
2026-527106-20-00Kidney transplantation
DrugsMycophenolate Mofetil·Tacrolimus
Oslo Universitetssykehus HF
Microbiological Phenomena
Norway
21/09/2026
Phase II
Learning From Early Aficamten In HCM (LEAF-HCM)
2025-523090-42-00Hypertrophic cardiomyopathy
DrugsAficamten·[68Ga]Ga-FAPI-46
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Cardiovascular Diseases
Netherlands
21/09/2026
Phase II
A Phase 2b, randomized, placebo-controlled, observer-blind study in adults 60 years and older to evaluate the efficacy, safety, and immunogenicity of a bivalent protein vaccine candidate against Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (HMPV)
2026-526177-42-00Infections and infestations
Sanofi Vaccines US Inc.
Virus Diseases
Estonia, Spain, Germany, Czechia, Poland, Finland, Netherlands
21/09/2026
Phase II
A Multicenter, Open-Label, Phase II Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age with Systemic Lupus Erythematosus.
2025-524578-41-00Systemic Lupus Erythematosus
DrugAnifrolumab
AstraZeneca AB
Immune System Diseases
Belgium, Portugal, Netherlands
21/09/2026
Phase II
An Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of ORKA-001 in Participants with Moderate-to-Severe Plaque Psoriasis
2026-526898-42-00Moderate-to-Severe Plaque Psoriasis
DrugORKA-001
Oruka Therapeutics Inc.
Skin and Connective Tissue Diseases
Spain, Germany
21/09/2026
Phase II
Randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of 2 dose levels of the oral ghrelin receptor agonist AC01 over 12 weeks in patients with chronic advanced heart failure with reduced ejection fraction (HFrEF)
2025-524469-25-00chronic advanced heart failure with reduced ejection fracti…
AnaCardio AB
Cardiovascular Diseases
Czechia, Slovakia, Spain, Bulgaria, Netherlands, Italy, Poland, Germany, Sweden, Hungary
21/09/2026
Phase IV
A Pragmatic Randomized Trial to Evaluate the Relative Effectiveness of Abrysvo® Revaccination Versus a Single Primary Dose for Preventing RSV-associated Lower Respiratory Tract Disease in Immunocompromised Adults (DAN-RSV IC REVAX)
2026-527536-14-00Respiratory syncytial virus infection
DrugVaxzevria
Region Hovedstaden, Pfizer Inc.
Virus Diseases
Denmark
21/09/2026
Phase I
A multicentre, single-arm, open-label, non-randomised pilot clinical trial to assess the dose-dependent effect of tirzepatide on gastric emptying in adult patients with type 1 diabetes
2026-527062-72-00Type 1 Diabetes.
Fundacion Para La Investigacion Biomedica Del Hospital Universitario Ramon Y Cajal
Immune System Diseases
Spain
18/09/2026
Phase III
A Randomized, Double-Blind, Head-to-Head Phase 3 Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone at 52 Weeks in Adults with Idiopathic Pulmonary Fibrosis (SURPASS-IPF)
2025-524493-42-00Idiopathic Pulmonary Fibrosis
DrugsDeupirfenidone·Pirfenidone
Puretech Lyt 100 Inc.
Respiratory Tract Diseases
Greece, Italy, Czechia, France, Portugal, Denmark, Spain, Poland, Germany, Romania, Belgium, Netherlands
18/09/2026
Phase III
A Multicentre, Parallel-Group, Observer-Blind, Randomised, Placebo-Controlled, Pivotal Trial Investigating the Safety and Immunogenicity of Group B Streptococcus Vaccine (GBS-NN/NN2) in Pregnant Women and Infants Born to Pregnant Women Vaccinated During Pregnancy
2026-525385-21-00Prevention of Group B streptoccoccus infection
Minervax ApS
Bacterial Infections and Mycoses
Czechia, Belgium, Denmark, Spain
18/09/2026
Phase IV
Multicentre, randomized, open label study comparing the concomitant administration of trabectedin and low-dose radiotherapy versus trabectedin alone in patients with advanced sarcoma
2026-525703-27-00Soft tissue sarcoma, osteosarcoma, or Ewing's sarcoma
DrugTrabectedin
Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz
Musculoskeletal Diseases
Spain
18/09/2026
Phase II
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Moderate to Severe Atopic Dermatitis (SIERRA1)
2025-524384-20-00Atopic dermatitis (AD)
DrugSoquelitinib
Corvus Pharmaceuticals Inc.
Skin and Connective Tissue Diseases
Italy, Czechia, Germany, Poland, Spain, Bulgaria
18/09/2026
Phase III
A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With Recurrent Platinum-Sensitive Ovarian Cancer
2025-524202-15-00Recurrent Platinum-Sensitive Ovarian Cancer
DrugsPegfilgrastim·Doxorubicin·Paclitaxel·Bevacizumab
Genmab A/S
Neoplasms
Czechia, Netherlands, Lithuania, Ireland, Finland, Hungary, Spain, Greece, Italy, France, Germany, Poland
18/09/2026
Phase III
A Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Once-Daily oral ASC30 in Adult Participants with Obesity or Overweight with Weight-Related Comorbidities (AURORA-1)
2026-526172-23-00Obesity or Overweight
DrugASC30
Ascletis Pharma (China) Co. Ltd.
Nutritional and Metabolic Diseases
Germany, Greece, Czechia, Poland
18/09/2026
Phase I
An Open-Label, Controlled, Multiple-Dose Phase I Clinical Trial Evaluating the Steady-State Pharmacokinetics, Pharmacodynamics and Safety of SHR-3167 in Subjects With Type 2 Diabetes
2026-525932-40-00Type 2 diabetes mellitus
Jiangsu Hengrui Pharmaceuticals Co. Ltd.
Nutritional and Metabolic Diseases
Germany
18/09/2026
Phase IV
Antibiotic Prophylaxis in Hematopoietic Stem Cell Transplantation: a Randomised Controlled Trial - The ANTURA trial
2025-524982-25-00Primary immunodeficiencies and other non‑malignant disorder…
DrugLevofloxacin
HUS-yhtymae
Hemic and Lymphatic Diseases
Finland
18/09/2026
Phase II
Prevention of venous thromboembolism in cirrhotic patients with hepatocellular carcinoma
2026-526857-33-00liver cirrhosis and hepatocellular carcinoma
DrugTinzaparin
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Neoplasms
Italy
17/09/2026
Phase III
A Long-Term Follow-Up Study of Subjects Completing the AU-011-301 (CoMpass) Trial of Bel-sar for Early Choroidal Melanoma (Indeterminate Lesions/Small Choroidal Melanomas)
2025-524405-33-00Choroidal Melanoma
Aura Biosciences Inc.
Neoplasms
Austria, Netherlands, Belgium, Czechia, Spain, France, Germany, Italy
17/09/2026
Phase II
BASTION – Phase II Trial of BrECADD in HIV-Positive Patients with Advanced-Stage Classic Hodgkin Lymphoma
2025-521749-26-00Advanced Stage Classic Hodgkin Lymphoma
DrugsBrentuximab Vedotin·Dacarbazine·Doxorubicin·Etoposide
University Of Cologne
Hemic and Lymphatic Diseases
Germany
17/09/2026
Phase III
A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination with the Modified Gemcitabine and nab-Paclitaxel Regimen Versus the Standard Gemcitabine and nab-Paclitaxel Regimen for the Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma Cancer (MAPKeeper 301)
2026-525617-31-00Metastatic Pancreatic Ductal Adenocarcinoma
DrugsGemcitabine·Paclitaxel
Immuneering Corp.
Neoplasms
Spain, Czechia, Hungary, Belgium, Poland, Germany, France, Italy, Romania
17/09/2026
Phase I/II
A follow-up extension study of patients who completed the U-LaserPrint-1 clinical trial to evaluate the long-term safety and efficacy of treatment with InvivoLPrint-U.
2026-527804-26-00Muscle-invasive bladder cancer (MIBC) patients, eligible fo…
Phosprint S.A.
Neoplasms
Greece
17/09/2026
Phase III
A phase III, randomised, double-blind, placebo-controlled, multicentre trial comparing efficacy and safety of trilaciclib versus placebo in participants with limited-stage small cell lung cancer
2025-525026-35-00Limited-stage small cell lung cancer (LS-SCLC)
Pharmacosmos A/S
Neoplasms
Czechia, Greece, France, Belgium, Italy, Spain, Germany
17/09/2026
Phase III
A Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Once-Daily Oral ASC30 in Adult Participants with Obesity or Overweight with Type 2 Diabetes Mellitus (AURORA-2)
2026-526336-39-00Obesity or Overweight with Type 2 Diabetes Mellitus
DrugASC30
Ascletis Pharma (China) Co. Ltd.
Nutritional and Metabolic Diseases
Germany, Czechia, Greece, Poland
17/09/2026
Phase II
The Role of Serotonin 4 Receptor Agonism in Regulating Mood and Cognition in Depression in women (RECAP-D)
2026-526685-25-00Major depressive disorder
DrugsPrucalopride·Sertraline
Region Hovedstaden
Mental Disorders
Denmark
17/09/2026
Phase III
Zenagamtide use for the reduction of risk of major adverse cardiovascular events in people with established atherosclerotic cardiovascular disease and either overweight or obesity (AMBIENCE)
2026-525182-53-00Atherosclerotic cardiovascular disease and either overweigh…
Novo Nordisk A/S
Cardiovascular Diseases
Denmark, Czechia, Greece, France, Italy, Germany, Spain, Poland, Netherlands, Bulgaria
16/09/2026
Phase III
A Phase 3 Randomized Study Comparing Ramantamig Plus Daratumumab Versus Investigator’s Choice of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy.
2026-526654-14-01Newly Diagnosed Multiple Myeloma
DrugsRamantamig·Velcade·Bortezomib·Daratumumab
Janssen Cilag International
Neoplasms
Greece, Portugal, Italy, France, Netherlands, Czechia, Germany, Poland, Spain
16/09/2026
Phase II
A phase II randomised trial investigating the benefit of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy for resectable NSCLC (ADIL)
2025-524439-38-00Non Small Cell Lung Cancer (NSCLC)
DrugDurvalumab
Oslo Universitetssykehus HF
Respiratory Tract Diseases
Sweden, Norway, Denmark
16/09/2026
Phase III
A Phase 2/3, Randomized, Double-blind, Multicenter, Placebo-Controlled Study Of Inebilizumab In Participants With Autoimmune Hepatitis
2025-522393-37-00Autoimmune Hepatitis (AIH)
DrugInebilizumab
Amgen Inc.
Digestive System Diseases
Belgium, Germany, Hungary, Czechia, Bulgaria, France, Netherlands, Italy, Poland, Greece, Portugal, Spain
16/09/2026
Phase III
A Phase 3a, observer blind, randomized, controlled study to evaluate the immunogenicity and safety of intramuscular administration of an investigational combined measles, mumps, rubella, and varicella vaccine compared with intramuscular administration of ProQuad when administered as a second dose to healthy children aged 15 months to 6 years of age
2025-523274-17-00Measles, mumps, rubella, varicella
GlaxoSmithKline Biologicals
Virus Diseases
Spain, Germany
16/09/2026
Phase II
A single-centre, Phase 2, open-label study to investigate ovulation inhibition after the administration of different dosages of dienogest tablets in combination with different dosages of drospirenone tablets with regular intake and after intentional intake errors in healthy premenopausal female participants
2026-526788-39-00Contraception/Pregnancy prevention in healthy subjects
DrugDienogest
Gedeon Richter Plc.
Reproductive and Urinary Physiological Phenomena
Germany
16/09/2026
Phase III
Randomized double-blinded placebo-controlled study of the efficacy of fluoxetine in add-on treatment of drug-resistant, complex and rare epilepsy in children aged 8 years and older: use of a design evaluating the time to reach a defined number of seizures for each child during the prospective observational phase (FLUOXEPIL)
2024-519897-38-01complex and rare epilepsy in children aged 8 years and older
DrugFluoxetine
Centre Hospitalier Regional De Marseille
Nervous System Diseases
France
15/09/2026
Phase I
A clinical trial to learn about the effects of IEV407 when given alone or with endocrine therapy in people with advanced breast cancer
2025-522707-26-00Advanced HR+/HER- breast cancer
Novartis Pharma AG
Neoplasms
Germany, France, Netherlands, Spain, Italy
15/09/2026
Phase I
Clinical study to evaluate the safety and efficacy of a new targeted radioactive drug treatment for advanced prostate cancer
2026-525244-14-00Metastatic prostate cancer
Fondazione IRCCS Istituto Nazionale Dei Tumori
Neoplasms
Italy
15/09/2026
Phase IV
Attachment Development and Learning in ADHD: The Role of Dopamine.
2025-525122-35-00Attention-Deficit/Hyperactivity Disorder (ADHD)
UZ Leuven
Mental Disorders
Belgium
15/09/2026
Phase II
A Phase II, randomized, blinded, dose selection study to assess safety and preliminary efficacy of antithrombotic heparin proteoglycan mimetic APAC (antiplatelet, anticoagulant) administered locally to the site of arterio-venous fistula (AVF) surgery to facilitate maturation of hemodialysis (HD) vascular access in patients with end stage kidney disease (ESKD) (MATURATION)
2026-526207-30-00End stage kindey disease
DrugHeparin
Aplagon Oy
Not possible to specify
Sweden, Spain, Finland
15/09/2026
Phase II
Multicenter, open label, phase II clinical trial of inotuzumab ozogamicin as prophylaxis for relapse in patients with high-risk acute B-cell precursor acute lymphoblastic leukaemia after allogeneic stem cell haemotopoietic transplantation
2026-525964-17-00Acute lymphoblastic leukaemia
DrugInotuzumab Ozogamicin
Fundacion PETHEMA
Neoplasms
Spain
15/09/2026
Phase II
J2S-MC-GZMV: A Phase 2, Multicenter, Randomized, Double-Blind, 52-week Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
2026-525480-41-00Pulmonary Disease, Chronic Obstructive
DrugBrenipatide
Eli Lilly & Co.
Respiratory Tract Diseases
Denmark, France, Romania, Czechia, Poland, Hungary, Germany, Austria
15/09/2026
Phase IV
Effects of General Anaesthetic Agents on the Efficacy of Electroconvulsive Therapy and EEG Changes in Patients with Depression
2025-524829-40-00Severe unipolar depression treated with electroconvulsive t…
DrugsEtomidate·Propofol
Varsinais-Suomen hyvinvointialue
Mental Disorders
Finland
15/09/2026
Phase IV
REconsidering Long-TErm ASpirin in the Elderly in Secondary Prevention of Coronary Artery Disease (RELEASE) Norway: A Randomised, Registry-based Trial
2026-526941-91-00Chronic coronary syndrome
Vestre Viken HF
Circulatory and Respiratory Physiological Phenomena
Norway
15/09/2026
Phase I
Detection of rEPO using Dried Blood Spot (DBS)
2026-526613-29-01healthy participants
Consorci Mar Parc De Salut De Barcelona
Not possible to specify
Spain
15/09/2026
Phase II
Interventional, randomized, double-blind, parallel-group, placebo-controlled, flexible-dose trial of Lu AF28996 in adults with Parkinson’s disease experiencing motor fluctuations.
2025-524655-30-00Parkinson’s disease
H. Lundbeck A/S
Nervous System Diseases
Czechia, France, Spain, Poland, Italy, Germany, Sweden
15/09/2026
Phase II
Optimization of De-EscalatiON strategies in early breast cancer
2026-527524-27-00breast cancer
DrugsTrastuzumab emtansine·Exemestane·Anastrozole·Abemaciclib
Istituto Di Candiolo Fondazione Del Piemonte Per L'Oncologia IRCCS
Neoplasms
Italy
14/09/2026
Phase I
Study of the distribution of linezolid in the prostate in patients who underwent endoscopic prostate enucleation – DiProLine
2026-527015-42-00A Study of the Distribution of Linezolid in the Prostate in…
Centre Hospitalier Le Mans
Male Urogenital Diseases
France
14/09/2026
Phase I
Comparative bioavailability study of Colistin Cyclops® administered as 3 different doses
2025-524657-14-00No therapeutic indication in the current bioavailability tr…
CCDRD Cooperative Clinical Drug Research and Development AG, PureIMS B.V.
Respiratory Tract Diseases
Bulgaria
14/09/2026
Phase III
An Open-label, Multi-Center, Single-arm Prospective Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex®-C plus Standard Medical Treatment to Prevent Infections in Participants with Secondary Antibody Deficiency Associated with Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma (Sigma).
2026-526803-31-00Secondary Antibody Deficiency Associated with Chronic Lymph…
Grifols Therapeutics LLC
Immune System Diseases
Italy, Poland, Czechia, France, Spain
14/09/2026
Phase I/II
A study assessing the safety, tolerability, pharmacokinetics and efficacy of single and multiple doses of NNC0638-0355 in participants with overweight or obesity
2026-526797-16-00Obesity and overweight
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Netherlands
14/09/2026
Phase I
A Study to Evaluate the Safety, Tolerability, and Activity of a Novel Oral Anticancer Drug (FLC‑436) in Patients With Refractory or Relapsed Solid Malignancies
2026-526215-10-00Refractory or Relapsed Solid Malignancies
Fileclo Sp. z o.o.
Neoplasms
Poland
14/09/2026
Phase I
A study to evaluate how well linaprazan glurate is absorbed and how it controls stomach acid (Part I) and investigation of the influence of a meal on the blood levels of linaprazan glurate (Part II) in healthy volunteers
2026-527465-30-00Healthy volunteer
Cinclus Pharma Holding AB (publ)
Bacterial Infections and Mycoses
Germany
14/09/2026
Phase II
A multicenter, randomized, double-blind, placebo- controlled Phase 2 study to investigate the efficacy, safety and tolerability of remibrutinib (LOU064) in adult patients with Papulopustular Rosacea (PPR)
2025-524496-23-00Papulopustular Rosacea (PPR)
DrugRemibrutinib
Novartis Pharma AG
Skin and Connective Tissue Diseases
Bulgaria, Spain, France, Italy, Germany
14/09/2026
Phase II
COLIBRI-GI_Randomized phase 2 study of second-line chemotherapy comparing FOLFIRI + ivonescimab versus FOLFIRI + bevacizumab in Microsatellite Stable (MSS)/ proficient MisMatch Repair (pMMR) BRAF wild type (wt) advanced colorectal cancer (mCRC) without liver metastases
2025-524215-36-00Patients with non resectable pMMR/MSS BRAF wt mCRC, without…
DrugsFolinic acid·Ivonescimab·Fluorouracil·Leucovorin
Unicancer
Neoplasms
France
11/09/2026
Phase IV
A Rollover Study to Follow the Long-term Durability of Response to UGN-103 in Participants From Study BL013
2026-526359-75-00Non-Muscle Invasive Bladder Cancer
DrugMitomycin C
Urogen Pharma Ltd.
Neoplasms
Estonia, Romania, Spain, Bulgaria, Latvia
11/09/2026
Phase II
Attenuating Calciprotein particles Transformation and Inhibiting Vascular calcification Evolution by Sodium ThioSulphate trial
2026-525680-41-00Vascular Calcification
Radboud universitair medisch centrum Stichting
Therapeutics
Netherlands
11/09/2026
Phase I
Targeting fibrotic tissue with a radioactive-labelled Fibrobody, visible using a full-body PET/CT scan (FibroVision)
2025-521143-20-00Bone Morphogenic Protein Receptor type 2 mutation carriers …
Amsterdam UMC Stichting
Diagnosis
Netherlands
10/09/2026
Phase I
A Phase 1b Basket Study Evaluating B Cell Depletion in Blood and Tissue by Etentamig or ABBV-519 in Subjects with Moderate to Severe Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), or Sjögren's Disease (SjD)
2026-526282-25-00Systemic lupus erythematosus, sjögren's disease and rheumat…
AbbVie Deutschland GmbH & Co. KG
Immune System Diseases
Germany
10/09/2026
Phase I
Evaluation of the bioequivalence of two intravaginal gel preparations containing 90 mg progesterone
2025-520498-38-00No therapeutic indication in the current trial with healthy…
CCDRD Cooperative Clinical Drug Research and Development AG, Ioulia And Irene Tseti Pharmaceutical Laboratories S.A.
Physiological processes
Bulgaria
10/09/2026
Phase II
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adult Participants with Moderate-to-Severe Atopic Dermatitis
2026-526184-38-00Atopic Dermatitis
DrugENV-294
Enveda Therapeutics Inc.
Skin and Connective Tissue Diseases
Germany, Czechia, Bulgaria, Poland, Spain
10/09/2026
Phase III
SCARP-DIAL (SGLT2i for CARdiovascular Protection in DIALysis)
2026-526075-35-00Chronic dialysis, Cardiovascular disease
DrugDapagliflozin
Karolinska University Hospital
Reproductive and Urinary Physiological Phenomena
Sweden
10/09/2026
Phase I
A PHASE I FIRST-IN-HUMAN, OPEN-LABEL, MULTICENTER STUDYTO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY ANTITUMOR ACTIVITY OF SIM0505 IN ADULT PARTICIPANTS WITH ADVANCED SOLID TUMORS
2026-525888-40-00Advanced solid tumors
Nextcure Inc.
Neoplasms
Italy, Poland, France, Spain
09/09/2026
Phase IV
AIRITY: A hybrid cross-sectional and prospective study to assess patient characteristics, disease burden, disease control, phenotypes, endotypes, and outcomes in a real-world setting in patients with asthma
2025-524916-13-00Asthma
Sanofi-Aventis Recherche & Developpement
Respiratory Tract Diseases
France, Spain, Germany, Italy
09/09/2026
Phase III
C6491013 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Once-Monthly PF-08653944 in Adults with Overweight or Obesity (VESPER 6)
2026-525318-75-00Overweight or Obesity
DrugBerobenatide
Pfizer Inc.
Nutritional and Metabolic Diseases
Spain, France, Germany, Poland, Italy
09/09/2026
Phase II
Pilot study with Low-dose nivolumab in Advanced Neoplasms that are TMB-high
2026-525445-73-00TMB-high advanced neoplasms
DrugNivolumab
UZ Brussel
Neoplasms
Belgium
09/09/2026
Phase I
GRT-2U101: A randomized, double-blind, placebo-controlled single and multiple ascending dose study to evaluate safety, tolerability, and pharmacokinetics/pharmacodynamics of GRT-002 in healthy volunteers and patients with chronic spontaneous urticaria after single or multiple intravenous or subcutaneous dosing of GRT-002 (BASALT trial).
2026-526293-16-00Chronic Spontaneous Urticaria
Granite Bio AG
Skin and Connective Tissue Diseases
Germany
09/09/2026
Phase II
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Semaglutide Subcutaneous Depot (CAM2056) in People with Obesity or Overweight
2026-526951-79-00Body weight management
Camurus AB
Nutritional and Metabolic Diseases
Germany
09/09/2026
Phase II
A Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long Term Safety and Tolerability of KT-621 in Participants With Asthma Previously Enrolled in a KT-621 Asthma Study
2026-526241-98-00Uncontrolled Moderate to Severe Eosinophilic Asthma
DrugKT-621
Kymera Therapeutics Inc.
Immune System Diseases
Austria, Germany, Belgium, Romania, Italy, Slovakia, Poland, Spain
09/09/2026
Phase IV
Randomized study evaluating the impact of an innovative and cooperative pathway integrating oncogeriatric, pharmaceutical and pharmacological follow-up in elderly patients (>70 years old) presenting with cancer and treated with oral therapy _ POG
2025-523610-83-00Elderly patients (>70 years old) presenting with cancer and…
DrugsBrigatinib·Pazopanib·Sunitinib·Alectinib
Institut Gustave Roussy
Immune System Diseases
France
08/09/2026
Phase I
A study of IDE892 as monotherapy and combination in MTAP-deleted Advanced Solid Tumors
2025-524715-37-00MTAP-Deleted Advanced Solid Tumors
Ideaya Biosciences Inc.
Diagnosis
Spain, France
08/09/2026
Phase I
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
2025-523601-16-00Lymphoma, Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Foll…
Eli Lilly & Co.
Hemic and Lymphatic Diseases
Spain, Poland, Italy, France, Germany
08/09/2026
Phase III
A Phase 3, Open-Label, Multicenter, Randomized Study of Subcutaneous vs Intravenous Tarlatamab in Participants with Relapsed Extensive-Stage Small Cell Lung Cancer After Platinum-based First-line chemotherapy (DeLLphi-315)
2026-525489-23-00Relapsed Extensive-Stage Small Cell Lung Cancer After Plat…
DrugsSiltuximab·Tarlatamab
Amgen Inc.
Neoplasms
Romania, Poland, Germany, Greece, Netherlands, Hungary, Portugal, France, Belgium, Italy, Spain
08/09/2026
Phase IV
A double-blind, randomised, 30-week placebo-controlled phase IV study to assess the efficacy and safety of osilodrostat in patients with hypertension caused by hypercortisolaemia due to Cushing’s Syndrome
2025-524649-28-00Cushing's syndrome
DrugOsilodrostat
Recordati AG
Hormonal diseases
Germany, Bulgaria, France, Romania, Italy, Poland, Spain
08/09/2026
Phase I/II
A Phase Ia/II Randomized Controlled Trial of Daratumumab Alone Versus Daratumumab Plus Abatacept for resistant active Antibody-Mediated Rejection in Kidney Transplant Recipients
2026-526730-73-00active Antibody-Mediated Rejection in Kidney Transplant Re…
Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca
Immune System Diseases
Spain
08/09/2026
Phase III
A Phase 3 Safety and Efficacy Trial of FLT201 Gene Therapy in Patients with Gaucher Disease Type 1
2025-520765-50-00Gaucher Disease Type 1
DrugsSirolimus·Tacrolimus
Spur Therapeutics Limited
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Spain
08/09/2026
Phase I
A clinical trial to learn about the effects of 225Ac-ETN029 in people with advanced solid tumors
2024-519111-34-00Small Cell Lung Cancer (SCLC), Neuroendocrine Prostate Canc…
Novartis Pharma AG
Neoplasms
France, Spain, Italy, Germany
08/09/2026
Phase II
A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Participants with Sjogren’s Disease-Associated Sensorimotor or Sensory Polyneuropathy
2026-526218-10-00Sjogren’s Disease-Associated Sensorimotor Polyneuropathy (S…
Argenx
Immune System Diseases
Germany, Estonia, Lithuania, Portugal, Slovakia, Hungary, Romania, Poland, Spain, Austria, Belgium, France, Bulgaria
08/09/2026
Phase III
EFC18362 - A Phase 3, multicenter, multinational, randomized, open-label, active-comparator study to evaluate the efficacy and safety of venglustat compared with Cerezyme in pediatric participants 2 to 11 years of age with Gaucher disease type 3 who have reached therapeutic goals with enzyme replacement therapy
2026-525374-19-00Immune system diseases
DrugImiglucerase
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Hungary, Italy, France, Finland, Germany, Spain
08/09/2026
Phase IV
POISON – Perioperative Safety and Effective Opioid Dosing in Chronic Opioid Use – a Randomized Clinical Study
2026-526719-13-00Opioid dependent chronic pain
DrugOxycodone
Region Hovedstaden
Anesthesia and Analgesia
Denmark
08/09/2026
Phase II
SemenGlutide: A randomized double-blinded, placebo-controlled, single-center, clinical trial comparing the effects of s.c. Semaglutide 2.4 mg once-weekly versus placebo on sperm concentration in overweight infertile men
2026-527538-29-00Infertility, overweight
DrugSemaglutide
Region Hovedstaden
Male Urogenital Diseases
Denmark
08/09/2026
Phase II
Effects of semaglutide as add-on therapy to sulfonylurea on plasma glucose in individuals with HNF1A- and HNF4A-MODY – A Steno MODERN-MODY project (MM-SEMA)
2025-523414-89-00Maturity-onset diabetes of the young type 3 (HNF1A-MODY), M…
DrugSemaglutide
Steno Diabetes Center Copenhagen
Hormonal diseases
Denmark
08/09/2026
Phase IV
A Phase IV, open label, single arm trial to assess the safety and immunogenicity of BIMERVAX® XFG.1.1 against SARS-CoV-2 Omicron XFG.1.1 variant.
2026-527363-16-00COVID-19
Hipra Scientific S.L.
Virus Diseases
Spain
07/09/2026
Phase II
A Phase 2, Randomized, Open-label, Study Assessing the Safety, Tolerability and Efficacy of Imzokitug in Combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as First-line Treatment for Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
2026-525170-19-00Locally Advanced or Metastatic Non-Small Cell Lung Cancer (…
DrugsVedolizumab·Infliximab·Pemetrexed·Paclitaxel
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Italy, Spain, Romania, Germany, France
07/09/2026
Phase I
A research study looking into how a high dose of s.c. semaglutide works with emptying of the stomach in people with excess body weight
2026-526083-20-00Participants with obesity
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Austria
07/09/2026
Phase II
"Evaluation of the impact of the dose of heparin on the occurrence of DWI ischemic lesions after embolization of unruptured intracranial aneurysm" "HARMONI"
2026-526530-13-00Intracranial aneurysms
DrugsAcetylsalicylic acid·Ticagrelor
Centre Hospitalier Universitaire De Bordeaux
Nervous System Diseases
France
07/09/2026
Phase I/II
A Long-Term Follow-Up Study to Assess the Safety and Efficacy of B-Cell-Directed Therapy in Patients with Systemic Autoimmune Disease (B-CARE)
2026-526888-37-00systemic autoimmune diseases
Universitaetsklinikum Erlangen AöR
Immune System Diseases
Germany
07/09/2026
Phase I
A trial to learn how safe anifrolumab is, how it moves throughout the body over time, and how it affects the body of adults with systemic lupus erythematosus
2026-526171-32-00Systemic Lupus Erythematosus
AstraZeneca AB
Immune System Diseases
Poland, Hungary
07/09/2026
Phase III
Zoledronic acid as prophylaxis against glucocorticoid-induced osteoporosis in lymphoma
2026-527220-27-00Large B-cell lymphomas, transformations of indolent B-cell …
DrugZoledronic Acid
Region Nordjylland
Neoplasms
Denmark
07/09/2026
Phase I
A Study to Learn How Different Manufactured Products of the Study Medicine Called Osivelotor (PF-07940367) Taste and Are Taken Up Into the Blood When Mixed With Soft Foods or Liquids Given on an Empty Stomach or Given With Food or an Acid Reducing Agent in Healthy Adults
2024-511410-20-01Sickle Cell Disease
Pfizer Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Belgium
07/09/2026
Phase I
A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis
2025-523980-39-00Rheumatoid arthritis (RA)
Eli Lilly & Co.
Immune System Diseases
Germany
07/09/2026
Phase I
Study of GS-2426 in Participants With Advanced Solid Tumors
2026-526264-20-00MTAP-Deleted Advanced Solid Tumors
Gilead Sciences Inc.
Neoplasms
Spain
07/09/2026
Phase I
A Study of RO7806767 as Single Agent and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors
2026-525215-13-00Advanced Solid Tumors
F. Hoffmann-La Roche AG
Neoplasms
Spain, Poland, Romania, Hungary, Germany, Italy, Belgium, Netherlands, Denmark, France
07/09/2026
Phase II
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1065890 in Adult Participants With Tardive Dyskinesia
2025-524104-30-00Tardive Dyskinesia
Neurocrine Biosciences Inc.
Nervous System Diseases
Bulgaria, Croatia, Romania, Slovakia, Czechia
07/09/2026
Phase I/II
Phase 1/2, first-in-human, randomized, double-blind, reference-controlled study to evaluate the safety and immunogenicity of an extemporaneously mixed Combo Inactivated Influenza Vaccine (Green Cross [GC]-IIV; 15µg of each hemagglutinin [HA])/OVX836 (480µg), in comparison to GC-IIV (15µg of each HA) concomitantly administered with OVX836 (480µg), GC-IIV alone (15 µg each HA), OVX836 alone (480µg), and a licensed reference trivalent IIV (Vaxigrip®; 15µg of each HA), administered intramuscularly (IM) in healthy participants
2026-526939-19-00Influenza disease
Osivax
Virus Diseases
Belgium
04/09/2026
Phase I
A Phase 1 study of a novel sublingual insulin formulation
2025-521863-11-00Type 1 diabetes mellitus
Sublin B.V.
Metabolism
Netherlands
04/09/2026
Phase II
A Multicenter, Open-Label, Single-Group Clinical Study to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab in Pediatric Subjects (aged 6 to 23 months) with Moderate-to-Severe Atopic Dermatitis Not Adequately Controlled with Topical Therapy
2025-525027-27-00Atopic Dermatitis
DrugNemolizumab
Galderma S.A.
Skin and Connective Tissue Diseases
Poland
04/09/2026
Phase II
Randomized, Double blind, Phase II Trial of Vortosiran to Evaluate Safety, Tolerability, and Pharmacodynamic Efficacy in Participants with Prior Venous Thromboembolism After Completion of Initial Anticoagulant Therapy (Cohort A) and in Cancer Patients at High Risk of Venous Thromboembolism (Cohort B)
2026-525479-15-00Venous Thromboembolism
DrugRBD4059
Ribocure Pharmaceuticals AB
Cardiovascular Diseases
Poland, Romania, France, Bulgaria
04/09/2026
Phase I
A Study to See How a New Compound, Trontinemab Affects the Body and Whether Immune Signals Triggered by it Affect How Other Medicines are Processed
2026-526756-31-00Not Applicable
F. Hoffmann-La Roche AG
Mental Disorders
Germany
04/09/2026
Phase I
An Open-Label, Phase 1 Dose-finding Study to Define the Maximum Tolerated Dose and Schedule of TRP-001 as Neoadjuvant Therapy in Treatment-naïve Very High-Risk Prostate Cancer Patients Eligible for Radical Prostatectomy with Extended Pelvic Lymph Node Dissection
2026-526406-32-00Prostate cancer
Torpedo Pharmaceuticals AG
Male Urogenital Diseases
Germany
04/09/2026
Phase I
A Phase I dose escalation study of intrapleural administration of Oncofid-P-M in patients with unresectable recurrent/progressive pleural mesothelioma after first-line treatment
2026-526119-12-00unresectable recurrent/progressive pleural mesothelioma
Fidia Farmaceutici S.p.A.
Neoplasms
Italy
03/09/2026
Phase III
Sequence Strategy of Immuneoncology (IO-IO) vs IO-tyrosine kinase inhibitors (TKI) followed by TKI in metastatic renal cell carcinoma (mRCC): A randomized phase 3 study Meet uro and FICOG trial. COMBO-Seq trial.
2025-523903-31-00Metastatic renal cell carcinoma
DrugsSorafenib·Sunitinib·Axitinib·Cabozantinib
Fondazione IRCCS Istituto Nazionale Dei Tumori
Neoplasms
Italy
03/09/2026
Phase II
BiFAST : A phase II trial evaluating fixed dose and faster ramp-up of epcoritamab with lenalidomide for 3L relapse/refractory large B-cell lymphoma after CAR T-cells therapy in 2nd line
2025-520895-24-003L relapse/refractory large B-cell lymphoma after CAR T-cel…
DrugsEpcoritamab·Lenalidomide
LYSARC
Hemic and Lymphatic Diseases
France
02/09/2026
Phase IV
ACTOR – AUC Control of Tacrolimus in Organ Recipients
2026-527107-22-00Kidney transplantation
DrugTacrolimus
Oslo Universitetssykehus HF
Therapeutics
Norway
02/09/2026
Phase II
Hyperthermic Intraperitoneal Chemotherapy and Regional Adrenalectomy in the management of Stage II & III Adrenocortical Carcinoma
2026-525406-36-00Adrenocortical Carcinoma
DrugsSodium Thiosulfate·Doxorubicin·Cisplatin
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
Neoplasms
Italy
02/09/2026
Phase II
Propranolol Dosefinding Assessment in Reactive Aggression Treatment (PRO-DART)
2026-526545-95-00Reactive aggression
DrugPropranolol
Radboud universitair medisch centrum Stichting
Behavior and Behavior Mechanisms
Netherlands
02/09/2026
Phase I
First-in-human evaluation of [11C]UCB-1A as imaging marker for synaptic vesicle glycoprotein 2C (SV2C): a PET study in healthy volunteers and participants with Parkinson’s disease
2026-526848-13-00Parkinson's disease
Karolinska Institutet
Nervous System Diseases
Sweden
02/09/2026
Phase IV
Reduced-dose versus full-dose systemic thrombolysis for high-risk pulmonary embolism: a multicentre, randomised, open-label, blinded-endpoint trial
2024-515904-37-00Pulmonary embolism
DrugAlteplase
Vaestra Goetalandsregionen, University Of Gothenburg
Cardiovascular Diseases
Denmark, Sweden, Norway
02/09/2026
Phase III
A parallel group, Phase 3, randomized, open-label, 2-arm study to demonstrate the superiority of belumosudil versus best available therapy (BAT) in participants at least 12 years of age with chronic graft versus host disease (cGVHD) refractory to or recurrent after 2 to 5 prior lines of systemic therapy
2026-525913-30-00Immune system diseases
DrugsBelumosudil·Ixazomib·Imatinib·Sirolimus
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Belgium, Czechia, Hungary, Sweden, Lithuania, Croatia, Netherlands, Slovakia, Poland, Austria, Norway, France, Italy, Bulgaria, Spain, Germany, Romania, Slovenia, Estonia, Portugal, Greece, Denmark
02/09/2026
Phase III
A phase III, randomized, prospective, double-blind, parallel design, multi-arm, multicenter study to compare the efficacy and safety of alogliptin and empagliflozin combination therapy versus alogliptin alone and empagliflozin alone in metformin-treated participants with type 2 diabetes mellitus and insufficient glycemic control despite diet and exercise (ODISSEIA 2026).
2025-524606-15-00Type 2 Diabetes mellitus
Tecnimede-Sociedade Tecnico-Medicinal S.A.
Nutritional and Metabolic Diseases
Poland, Germany, Portugal, Italy, Spain
02/09/2026
Phase III
Antibiotikapenetration og vævsrespons ved infektion og rekonstruktiv kirurgi i hoved-hals regionen
2026-526995-22-00Treatment and prevention of post operative infections
DrugsDicloxacillin·Cefuroxime·Amoxicillin
Region Midtjylland
Bacterial Infections and Mycoses
Denmark
02/09/2026
Phase I
A randomized, placebo-controlled trial, to evaluate the safety, immunogenicity and the optimal dose of MOPEVAC-Las vaccine candidate against Lassa Fever, in healthy volunteers consisting of an unblinded dose escalation and a blinded treatment phase (FIRST-IN-MOP)
2025-524034-26-02Lassa fever
Institut Pasteur
Virus Diseases
France
01/09/2026
Phase I
A study to test how well different doses of BI 4060107 are tolerated by people with advanced cancer (solid tumours)
2026-525187-18-00solid tumours
Aimed Bio lnc.
Neoplasms
France
01/09/2026
Phase I
PRadR 2 - A single center, open-label, Phase I study evaluating 161Tb-PSMA therapy in adult patients with metastatic clear cell renal cell carcinoma
2026-525526-38-00Metastatic clear cell renal cell carcinoma
Centre Leon Berard
Therapeutics
France
01/09/2026
Phase III
Effect of GABAergic treatments on cortical plasticity and motor learning capacity in the subacute phase after stroke: a single-case experimental study (GABAPLAST)
2026-526884-39-00Stroke
DrugGabapentin
Centre Hospitalier Universitaire De Toulouse
Nervous System Diseases
France
01/09/2026
Phase II
A phase II, open-label, randomized, multi-center study comparing the efficacy and safety of Sacituzumab govitecan versus investigator's choice in patients with cancer of unknown primary (CUP) who are relapsed after or refractory to platinum-based chemotherapy (SACICUP)
2025-523055-55-00Neoplasm
DrugsCalcium folinate·Sacituzumab Govitecan·Fluorouracil·Docetaxel
Universitaetsklinikum Heidelberg AöR
Neoplasms
Germany
01/09/2026
Phase II
Randomized, Multicenter, Vehicle-Controlled, Double-Masked Study to Evaluate the Efficacy and Safety of Intranasal Cenegermin (Recombinant Human Nerve Growth Factor [rhNGF]) in Adult Participants with Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
2025-524748-37-00Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
DrugCenegermin
Dompe' Farmaceutici S.p.A.
Eye Diseases
Denmark, Italy, Germany, Hungary, Netherlands, Spain, Belgium, France, Portugal
01/09/2026
Phase III
Randomized, controlled, multi-center trial to evaluate the efficacy, tolerability, and safety of an (S)-ibuprofen gel vs. placebo in the local symptomatic and short-term treatment of pain in acute contusions of the soft tissues following blunt trauma
2025-524451-31-00acute contusions of soft tissues
DrugParacetamol
Aponia Laboratories Inc.
Skin and Connective Tissue Diseases
Germany
01/09/2026
Phase II
A multicenter, prospective, randomized, placebo and non-surgical standard of care (NSSOC) controlled study, performed to evaluate the safety and efficacy of EscharEx and its placebo (gel vehicle) compared to NSSOC in participants with Venous Leg Ulcers (VLU)
2026-526070-16-00Venous Leg Ulcer (VLU)
DrugEscharEx
Mediwound Ltd.
Skin and Connective Tissue Diseases
Czechia, Slovakia
01/09/2026
Phase III
A Phase III Open-Label, Randomised, Multicentre Study of Consolidation with a Single Administration of AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against BCMA and CD19, Compared with Continuous Standard Therapy in Participants with NDMM Who Are Ineligible to Receive ASCT as Initial Therapy (DURGA-5).
2025-524014-29-00Newly Diagnosed Multiple Myeloma
DrugsAZD0120·Isatuximab·Bortezomib·Daratumumab
AstraZeneca AB
Neoplasms
Poland, Italy, Denmark, France, Sweden, Germany, Spain
01/09/2026
Phase II
A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of VQ-101 in participants with Parkinson’s disease carrying a heterozygous mutation of GBA1
2026-525848-15-00GBA1-associated Parkinson’s disease
Vanqua Bio Inc.
Nervous System Diseases
Netherlands, France, Spain, Germany
01/09/2026
Phase IV
Optimization of Dupilumab Maintenance Dosing in Eosinophilic Esophagitis: A Phase IV, Randomized, Controlled, Single-Blind, Non-Inferiority Study
2026-526348-11-01Eosinophilic Esophagitis
DrugDupilumab
Amsterdam UMC Stichting
Digestive System Diseases
Netherlands
01/09/2026
Phase III
A Phase 3, Randomized, Double-blind, Placebo‑controlled Study to Assess the Efficacy and Safety of Engasertib in Subjects With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)
2025-524490-17-00Hereditary Hemorrhagic Telangiectasia (HHT)
DrugEngasertib
Vaderis Therapeutics AG
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Hungary, Netherlands, Germany, Bulgaria, France, Italy, Lithuania, Spain, Belgium
31/08/2026
Phase II
Clinical Study of Local and Systemic biological Impact of GLP1/GIP-Receptor Agonists in patients with Breast Cancer: The CLARA trial
2026-525820-76-00Hormone Receptor positive postmenopausal breast cancer
DrugsTirzepatide·Letrozole
UZ Leuven
Neoplasms
Belgium
31/08/2026
Phase I/II
​​Perioperative zanidatamab combined with chemotherapy in HER2-positive locally advanced operable gastroesophageal adenocarcinoma (GEA): a Phase 1b/2a single-arm trial​
2025-523483-20-00Gastroesophageal adenocarcinoma (GEA)
DrugsZanidatamab·Tislelizumab
UZ Leuven
Neoplasms
Belgium
31/08/2026
Phase I/II
An Open-Label, Multicenter Phase 1/2 Study to Assess the Safety, Tolerability, and Efficacy of Intracochlear Ascending Dose Injections of SENS-601 Followed by Expansion Cohort in Pediatric Population With Hearing Loss Related to Biallelic Pathogenic Variation(s) of GJB2, As Well As to Demonstrate the Performance of the Administration System, Its Safety, Its Clinical Benefit, and Its Usability.
2026-525698-38-00Hearing Loss Related to biallelic pathogenic variation (s) …
Sensorion
Otorhinolaryngologic Diseases
France
31/08/2026
Phase III
A Phase 3, Randomized, Double-Blinded Study to Evaluate the Safety and Efficacy of Salanersen (BIIB115) After Onasemnogene Abeparvovec Treatment in Infants with Genetically Diagnosed Spinal Muscular Atrophy
2025-523857-32-00Spinal Muscular Atrophy
DrugSalanersen
Biogen Idec Research Limited
Nervous System Diseases
Portugal, Italy, Belgium, Croatia, Hungary, Germany, Ireland, France, Norway, Poland
31/08/2026
Phase II
A Phase II, single-arm trial on the addition of the DLL3xCD3 bispecific T-cell engager obrixtamig (BI 764532) to standard-of-care platinum-based first-line treatment of advanced large-cell neuroendocrine carcinoma of the lung (ALPINE 2)
2025-524345-28-00Male and female adult patients with locally advanced or met…
DrugObrixtamig
Technische Universitaet Dresden
Neoplasms
Germany
31/08/2026
Phase III
Evaluation of the Impact of a Strategy of Perioperative NSAID Suppression in Patients Undergoing Video-assisted Thoracic Surgery (VATS) on the Presence of Chronic Postoperative Pain (CPOP): a Randomised Clinical Trial (EVADRAINS)
2025-524917-96-00Thoracic surgery
DrugCalcium
Les Hopitaux Universitaires De Strasbourg
Not possible to specify
France
31/08/2026
Phase I
A research study looking at the effect of timing of meal after dosing and water volume at dosing on how the medicine zenagamtide is taken up by the body of participants with overweight or obesity
2025-521383-35-00overweight/obesity
Novo Nordisk A/S
Not possible to specify
Germany
31/08/2026
Phase III
Targeted versus standard peri-operative prophylaxis in patients colonized with carbapenemase-producing Enterobacterales undergoing liver transplantation: a stepped-wedge cluster randomization trial
2025-523453-34-00Patients colonized with CPE undergoing liver transplantatio…
DrugsEravacycline·Aztreonam·Tigecycline
Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico
Bacterial Infections and Mycoses
Italy
31/08/2026
Phase II
In-vivo fluorescence molecular bronchoscopy of durvalumab-680LT in patients with unresectable stage III NSCLC after chemoradiation - PulmoPrint
2026-526251-60-00Unresectable stage III non-small cell lung cancer
DrugDurvalumab
Universitair Medisch Centrum Groningen
Neoplasms
Netherlands
31/08/2026
Phase II
HOVON 168: Epcoritamab in Addition to R-Mini-CHOP Compared to R-Mini-CHOP in Elderly, Frail or Unfit Patients with Diffuse Large B-cell Lymphoma
2025-524230-25-00Diffuse large B-cell lymphoma (DLBCL)
DrugsEpcoritamab·Rituximab
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
Hemic and Lymphatic Diseases
Czechia, Denmark, Croatia, Spain, Sweden, Finland, Portugal, Ireland, Netherlands, Belgium, Norway
31/08/2026
Phase IV
Incidence and severity of postoperative delirium associated with Dexmedetomidine sedation during femur osteosynthesis in the elderly population
2025-523070-16-00Postoperative delirium
DrugsPropofol·Dexmedetomidine
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
Nervous System Diseases
Spain
31/08/2026
Phase I
REGN9220 in Combination with Odronextamab in Adult Participants with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)
2025-524780-20-00B-cell Non-Hodgkins Lymphoma (B-NHL)
Regeneron Pharmaceuticals Inc.
Hemic and Lymphatic Diseases
Belgium
31/08/2026
Phase II
Targeting IL-13 in Bullous Pemphigoid: An Investigator-Initiated, Prospective, Multicenter, Proof-of-Concept, Open-Label Pilot Study of Lebrikizumab
2026-525685-22-00Bullous pemphigoid
DrugLebrikizumab
Region Midtjylland, Region Sjaelland
Immune System Diseases
Denmark
31/08/2026
Phase II
Efficacy and safety of once-weekly subcutaneous UBT251 in participants with type 2 diabetes – a dose-finding study
2026-525465-42-00Type 2 diabetes (T2D)
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Spain, Hungary, Romania, Slovakia, Poland, Germany
31/08/2026
Phase IV
A prospective, randomized, double-blinded, placebo-controlled, cross-over study investigating the effects of metyrapone treatment on cardio-metabolic outcome parameters and chronobiology in patients with mild autonomous cortisol secretion
2026-526837-24-00Mild autonomous cortisol secretion
Medical University Of Vienna
Hormonal diseases
Austria
29/08/2026
Phase II
Paediatric sarcoma, hybrid imaging & FAPI – Raising the diagnostic standard for paediatric sarcoma patients combining novel radiotracer FAPI and whole-body PET/MRI
2025-524874-41-00Paediatric sarcoma
Drug[68Ga]Ga-FAPI-46
Rigshospitalet
Diagnosis
Denmark
28/08/2026
Phase I
An Open-Label Study of IDE034 in Adult Participants with Locally Advanced/Metastatic Solid Tumors
2026-526299-21-00Locally Advanced/Metastatic Solid Tumors -non-small cell l…
Ideaya Biosciences Inc.
Female Urogenital Diseases and Pregnancy Complications
Spain
28/08/2026
Phase IV
A prospective, exploratory, parallel-group, low-intervention, phase IV, randomized, double-blind, placebo-controlled, multi-center, national, 2-arm trial to investigate efficacy and safety of Amara-Tropfen (Amara drops) in patients with irritable bowel syndrome (IBS)
2026-526668-19-00Irritable Bowel Syndrome
Weleda AG
Digestive System Diseases
Germany
28/08/2026
Phase I/II
A Phase 1/2, Open-Label, Multicenter, Multi-cohort Study of S241656 as Monotherapy or in Combination with other Antileukemic Agents in participants with Selected Myeloid Malignancies
2025-525128-88-00Patients with Acute Myeloid Leukemia (AML), Myelodysplastic…
DrugPosaconazole
Institut De Recherches Internationales Servier IRIS
Neoplasms
Netherlands, Spain, Germany, Italy, France, Finland
27/08/2026
Phase IV
S-KETamine vs. propofol for prehospital sedation of patients with severe Acute Brain Injury: The KETABI randomised trial
2026-525588-41-00traumatic brain injury, subarachnoid haemorrhage, intracere…
DrugPropofol
Region Hovedstaden
Pathological Conditions, Signs and Symptoms
Denmark
27/08/2026
Phase I
Relative oral bioavailability and tolerability of hydrocortisone from 2-dimensionally printed orodispersible films in children and adolescents with primary adrenal insufficiency (REPLACE trial)
2026-526416-37-00adrenal insufficiency
Universitaetsklinikum Heidelberg AöR
Nutritional and Metabolic Diseases
Germany
27/08/2026
Phase III
A multicenter, open-label, single-arm, baseline-controlled trial to assess the efficacy and safety of lucerastat in treatment-naïve/pseudo-naïve adult male participants with Fabry disease
2026-525207-27-00Fabry disease
Idorsia Pharmaceuticals Ltd.
Nutritional and Metabolic Diseases
Germany, France
27/08/2026
Phase II
MDMA-assisted therapy for adolescents with treatment-resistant PTSD
2024-515184-65-01Post-traumatic stress disorder
Stichting Amsterdam UMC
Mental Disorders
Netherlands
26/08/2026
Phase II
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Oral PIPE-791 in Subjects with Idiopathic Pulmonary Fibrosis
2025-521901-42-00Idiopathic Pulmonary Fibrosis (IPF)
Contineum Therapeutics Inc.
Respiratory Tract Diseases
Italy, Belgium, Denmark, Austria, Greece, Germany, France, Netherlands, Portugal, Poland, Spain
26/08/2026
Phase II
C6461010 - An Interventional, Open-Label, Phase 2 Study to Investigate the Safety and Efficacy of PF-08634404 Monotherapy or in Combination in Adult Participants with Early-Stage Resectable or Locally Advanced Unresectable Non-Small Cell Lung Cancer
2025-524825-42-00Early-Stage Resectable or Locally Advanced Unresectable Non…
DrugsPF-08634404·Pemetrexed·Paclitaxel·Carboplatin
Pfizer Inc.
Neoplasms
Spain, France, Italy, Ireland, Germany, Poland
26/08/2026
Phase II
A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina S) in Participants With Advanced Gastrointestinal (GI) Cancers
2025-524130-26-00Gastrointestinal Cancers
DrugPegfilgrastim
Genmab A/S
Neoplasms
Italy, Belgium, France, Spain, Denmark, Netherlands, Germany
26/08/2026
Phase II
Development of a Short-Acting GH Suppression Test with subcutaneous short action Pasireotide (PAT) for Predicting Long-Term Response to Pasireotide LAR in Patients with Acromegaly
2025-524253-14-00Acromegaly
Instituto De Investigacion En Ciencias De La Salud Germans Trias I Pujol
Hormonal diseases
Spain
26/08/2026
Phase II
A Phase 2a, proof-of-concept, multicenter, double-blind, randomized, placebo-controlled, parallel-group trial to assess the efficacy and safety of ACT-777991 in adults with non-segmental vitiligo
2025-524865-25-00Non-segmental vitiligo
Idorsia Pharmaceuticals Ltd.
Skin and Connective Tissue Diseases
Czechia, Poland
26/08/2026
Phase I
Bioequivalence clinical trial of two formulations of empagliflozin/metformin
2026-527325-35-00Healthy volunteers
Laboratorios Normon S.A.
Not possible to specify
Spain
26/08/2026
Phase II
DIRECTION- Discontinuation versus continuation of riociguat monotherapy in chronic thromboembolic pulmonary hypertension successfully treated with balloon pulmonary angioplasty
2026-525351-81-00chronic thromboembolic pulmonary hypertension
DrugRiociguat
Assistance Publique Hopitaux De Paris
Cardiovascular Diseases
France
25/08/2026
Phase II
A Phase 2b, Randomized, Multicenter, Double-Blind, Dose-Finding, Active-Controlled Study of Siplizumab (TCD601) Compared to Rabbit Anti-Thymocyte Globulin in Renal Transplant Recipients Requiring Induction Therapy and Receiving Standard of Care Immunosuppression with Tacrolimus, Mycophenolic Acid and Corticosteroids (MODERNIZE 1)
2026-525646-29-00Renal Transplantation
DrugSiplizumab
Nefro Avillion Clinical Development LLC
Immune system processes
Czechia, Spain, Portugal, Austria
25/08/2026
Phase III
Tenecteplase for the treatment of acute stroke in the late time window before inter-hospital transfer for thrombectomy: a randomized controlled trial
2026-525280-40-00Acute ischemic stroke
DrugTenecteplase
Fondation A De Rothschild
Nervous System Diseases
France
25/08/2026
Phase II
[68]GA-FAPI-46 PET/CT for the diagnosis of metastatic lesions in patients with lobular breast cancer (ICL). FAPICL
2025-524897-40-00invasive lobular carcinomas of the breast
Drug[68Ga]Ga-FAPI-46
Hospices Civils De Lyon
Diagnosis
France
25/08/2026
Phase I
A single and multiple ascending dose study of DFL23693 in healthy volunteers
2026-527078-35-00Osteoarthritis
Dompe' Farmaceutici S.p.A.
Musculoskeletal Diseases
France
25/08/2026
Phase I
A Phase 1 Study of CTIM-76 in Patients with Recurring Ovarian Cancer and Other Advanced Solid Tumors
2025-523968-20-00Patients with Recurring Ovarian Cancer and Other Advanced S…
Context Therapeutics Inc.
Neoplasms
France, Spain
25/08/2026
Phase III
A Phase 3, open-label extension study to evaluate the long-term safety and efficacy of rozanolixizumab in adult participants with ocular myasthenia gravis
2025-524757-14-00Ocular Myasthenia Gravis
DrugRozanolixizumab
UCB Biopharma
Immune System Diseases
Hungary, France, Greece, Poland, Spain, Italy, Germany
25/08/2026
Phase III
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Efficacy and Safety Study of HBS-301 in Participants with Narcolepsy Followed by an Open-label Extension
2025-523821-17-00narcolepsy
DrugPitolisant
Harmony Biosciences Management Inc.
Nervous System Diseases
Belgium, Italy, Germany, France, Spain, Poland
25/08/2026
Phase I
A Phase 1 Trial to Evaluate the Safety, PK, and PD of AX-0811 in Healthy Participants
2026-526764-21-00Cholestatic disease
ProQR Therapeutics VIII B.V.
Digestive System Diseases
Belgium
25/08/2026
Phase I
The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used for lowering levels of cholesterol in the blood.
2026-527468-34-00No medical condition
Adamed Pharma S.A.
Not possible to specify
Czechia
25/08/2026
Phase II
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Camoteskimab in Adults with Moderate-to-Severe Atopic Dermatitis
2026-525673-39-00Atopic Dermatitis (AD)
Apollo Therapeutics Limited
Skin and Connective Tissue Diseases
Hungary, Czechia, Germany, Bulgaria, Poland, Spain
25/08/2026
Phase I
Bioavailability Comparison of Valsartan 320 mg Tablets (Test vs. Reference Product)
2026-527569-31-00Not applicable (submitted trial is a BE study in healthy pa…
ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.
Cardiovascular Diseases
Czechia
25/08/2026
Phase II
Phase 2 Randomized, Double-blind, Placebo-controlled Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
2025-524793-42-00Relapsed/Refractory Multiple Myeloma
Janssen Cilag International
Neoplasms
Sweden, Spain, Greece, Portugal, France, Hungary
25/08/2026
Phase II
Solid tumor Study for Long term Treatment of Cancer Patients Who Have Participated in BMS-Parent Studies Investigating Adagrasib (BMS-986503)
2025-524905-34-00Solid tumor
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Greece, Hungary, Poland, Belgium, Spain, Netherlands, Germany, France, Portugal, Italy, Romania
25/08/2026
Phase IV
Piperacillin/tazobactam or ampicillin and gentamicin for empirical treatment of community acquired infection: A randomised clinical trial (PAGER)
2026-526131-20-00Urosepsis, Infection of unknown origin, Pyelonephritis, Cys…
DrugsAmpicillin·Gentamicin
Region Hovedstaden
Bacterial Infections and Mycoses
Denmark
25/08/2026
Phase I
A Phase 1 Study of TT125-802 as Monotherapy and in Combination with Pomalidomide and Dexamethasone in Participants with Multiple Myeloma
2025-523536-39-00Relapsed and Refractory Multiple Myeloma
TOLREMO therapeutics AG
Neoplasms
Italy, Spain
24/08/2026
Phase I/II
A combined phase I/IIa trial to investigate the safety and pharmacokinetics of StaphAcute in healthy participants and patients with Staphylococcus aureus bacteremia - StaphAcute
2024-511586-10-01Phase IIa: patients with methicillin susceptible (MSSA) or …
University Of Cologne
Bacterial Infections and Mycoses
Germany
24/08/2026
Phase I
Proof of cOncept Study demonStrating the potential substitutIon of suBcutaneous Injection of recombinant human insulin by subLIngual administration of S.L.I.M®-Formulations in TYpe-I DIABEtic PaTiEntS
2025-524539-38-01Patients with diabete type 1 under pump
Sublin B.V.
Nutritional and Metabolic Diseases
France
24/08/2026
Phase III
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of Etifoxine Monotherapy in The Treatment of Adjustment Disorder with Anxiety (ADWA)
2025-524287-38-00Treatment of adjustment disorder with anxiety (ADWA).
Biocodex
Nervous System Diseases
Bulgaria, France, Romania, Czechia
24/08/2026
Phase III
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (modified FOLFIRINOX or Gemcitabine plus Nab-paclitaxel) with or without Zoldonrasib (RMC-9805) as First-line Treatment in Patients with Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma (RASolute 305)
2025-524928-21-00Pancreatic Adenocarcinoma
DrugRMC-9805
Revolution Medicines Inc.
Neoplasms
Sweden, Spain, France, Poland, Italy, Norway, Belgium, Germany, Czechia, Austria, Netherlands, Denmark
24/08/2026
Phase IV
Adalimumab Treatment for Patients with Hidradenitis Suppurativa at high risk of Progressing to Severe Disease: An Unblinded Randomized, Controlled Trial
2025-522505-37-00Hidradenitis suppurativa
DrugsDoxycycline·Adalimumab
Gentofte Hospital
Skin and Connective Tissue Diseases
Denmark
24/08/2026
Phase I/II
A Prospective Diagnostic Trial of Al[¹⁸F]F-NOTA-folate PET in Patients with Suspected Cardiac Sarcoidosis or Infective Endocarditis and Healthy Volunteers (FOL-CARD)
2026-526655-59-00Cardiac Sarcoidosis, Infective endocarditis
Turku University Hospital
Cardiovascular Diseases
Finland
24/08/2026
Phase III
Evaluation of the efficacy and safety of photodynamic therapy with BF-200 ALA (Ameluz®) in immunosuppressed patients with actinic keratoses and superficial basal cell carcinoma at any location.
2026-526649-85-00Immunosuppressed patients with premalignant and malignant s…
DrugGliolan
Dra. Elena González Guerra
Skin and Connective Tissue Diseases
Spain
24/08/2026
Phase II
A Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Potential Antiseizure Activity of Adjunctive OV329 Therapy in Adults with Drug-Resistant Focal Epilepsy
2026-525896-23-00Focal epilepsy
Ovid Therapeutics Inc.
Nervous System Diseases
Netherlands
21/08/2026
Phase III
FOSFOLD - Fosfomycin trometamol compared with another active antibiotic relay therapy for the treatment of acute Escherichia coli pyelonephritis in elderly women: a randomized, multicenter, non-inferiority trial
2025-521663-13-00Women aged 75 years or older presenting with E. coli pyelon…
DrugsCefotaxime·Ertapenem·Ceftazidime·Aztreonam
Assistance Publique Hopitaux De Paris
Female Urogenital Diseases and Pregnancy Complications
France
21/08/2026
Phase III
Surgery versus intra-lesional sclerosis with polidocanol (Aetoxisclerol) in labial venous malformations in children and adults: a randomized controlled trial - SASOV
2025-521374-34-00superficial labial venous malformation
Centre Hospitalier Regional Universitaire De Tours
Cardiovascular Diseases
France
21/08/2026
Phase III
A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase III Study to Evaluate the Efficacy and Safety of Letrozole SIE Compared to Femara® (both in Combination with the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women with HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer (SIE-3)
2025-524846-85-00​​HR-positive, HER2-negative, inoperable locally advanced o…
DrugsRibociclib·Letrozole
Laboratorios Farmaceuticos Rovi S.A.
Neoplasms
Romania, Spain, Bulgaria, Czechia, Latvia, Poland, Croatia, Slovakia
21/08/2026
Phase III
A Phase 3 Randomized, Double-blind, Placebo-controlled Global Study of Sapablursen in Polycythemia Vera
2025-524669-25-00Polycythemia Vera
Deciphera Pharmaceuticals Inc.
Hemic and Lymphatic Diseases
Austria, Czechia, Italy, Portugal, Germany, France, Hungary, Spain, Poland
21/08/2026
Phase III
A Phase 3, Randomized, Multicenter, Open-Label Study of Velzatinib (GSK6042981) versus Imatinib in Participants with Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST)
2025-524934-24-00Neoplasms, Gastrointestinal Stromal
DrugImatinib
Glaxosmithkline Research & Development Limited
Neoplasms
Italy, Portugal, Germany, Sweden, Poland, Romania, Finland, Greece, Norway, Spain, Netherlands, France, Hungary
21/08/2026
Phase III
A Multicenter, Randomized, Double-Blind, 2-Treatment Arm Study to Assess Comparative Pharmacokinetics, Efficacy, Safety and Immunogenicity Between Intravenous AVT32-DRL_PB and Keytruda® as an Adjuvant Treatment in Participants with Stage IIB/C-III Melanoma Following Complete Resection
2025-525093-11-00Stage IIB/C-III Melanoma
DrugPembrolizumab
Alvotech Swiss AG
Neoplasms
Romania, Spain
21/08/2026
Phase I
A randomized, double-blind, placebo-controlled clinical trial to investigate the human monoclonal antibody NG004 in acute, incomplete cervical spinal cord injury (SCI) patients
2026-526089-26-00Acute Incomplete Cervical Spinal Cord Injury
NovaGo Therapeutics AG
Nervous System Diseases
Germany
21/08/2026
Phase I/II
A multicenter, non-therapeutic, interventional, long-term follow-up clinical trial to evaluate the safety of autologous PRAME-directed TCR T cell therapy IMA203 or IMA203CD8 in patients with previously treated, advanced and/or metastatic solid tumors
2026-525827-25-00Solid tumors
DrugAnzu-cel
Immatics US Inc.
Neoplasms
Germany
21/08/2026
Phase III
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Subjects With α- or β-Non–Transfusion-Dependent Thalassemia (ENERGIZEKids)
2025-524706-15-00Non-Transfusion-Dependent Alpha- or Beta-Thalassemia
DrugMitapivat
Agios Pharmaceuticals Inc.
Hemic and Lymphatic Diseases
Italy, Greece
21/08/2026
Phase II
Èn dosis intravenøs penicillin som tillæg til peroral penicillin i behandlingen af akut tonsillitis, peritonsillær phlegmone og peritonsillær absces – et randomiseret, dobbeltblindet, placebo-kontrolleret studie
2026-526903-31-00Tonsillitis
DrugBenzylpenicillin
Region Midtjylland
Bacterial Infections and Mycoses
Denmark
21/08/2026
Phase III
A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator’s Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
2025-524641-27-00High-Grade Serous Ovarian, Fallopian Tube, or Primary Perit…
DrugsTopotecan·Doxorubicin·Gemcitabine·Paclitaxel
K-Group Beta Inc.
Neoplasms
Germany, Spain, Italy, Belgium, Poland, France, Ireland
21/08/2026
Phase I
A study to see how safe a new medicine (NNC0705-0002) is in healthy people
2026-526205-15-00Cardiometabolic
Novo Nordisk A/S
Not possible to specify
Netherlands
21/08/2026
Phase I
A Phase I Study using Oncolytic AdenoVirus Immunotherapy with Repeat Administrations in Recurrent GliOblastoma (VIRAGO)
2025-524555-31-00Recurrent Glioblastoma
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Nervous System Diseases
Netherlands
21/08/2026
Phase II
A Randomized, Double-Blind, Phase 2 Trial Evaluating the Efficacy, Safety and Tolerability of Primary Cardioprotection with Dapagliflozin in Patients with Newly Diagnosed Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation
2026-525418-67-00Multiple Myeloma
DrugDapagliflozin
Instytut Hematologii I Transfuzjologii
Hemic and Lymphatic Diseases
Poland
21/08/2026
Phase III
A 52-week multicenter, randomized, parallel-group trial in overweight people investigating lifestyle changes, mushroom supplementation and bupropion to reduce adiposity and cardiometabolic risk
2026-527136-13-00Overweight or class I obesity (BMI 25.0–34.9 kg/m²), with o…
DrugBupropion
Uppsala University
Nutritional and Metabolic Diseases
Sweden
21/08/2026
Phase III
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Subjects With α- or β-Transfusion-Dependent Thalassemia (ENERGIZEKids-T)
2025-524707-71-00Transfusion-Dependent Alpha- or Beta-Thalassemia
DrugMitapivat
Agios Pharmaceuticals Inc.
Hemic and Lymphatic Diseases
Italy, Greece
20/08/2026
Phase III
A Phase 3, Randomized, Open-Label Study of Linvoseltamab Versus Daratumumab in Participants with Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma
2025-523252-31-00High Risk Smoldering Multiple Myeloma (HR-SMM)
DrugsLinvoseltamab·Daratumumab
Regeneron Pharmaceuticals Inc.
Neoplasms
Italy, Spain, Poland, France, Norway, Greece, Germany
20/08/2026
Phase III
A Phase 3 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Efficacy of Gildeuretinol Acetate (ALK-001) on the Progression of Stargardt Disease (STGD) - NORTHSTAR
2026-525296-60-00Stargardt Disease (STGD1)
Alkeus Pharmaceuticals Inc.
Eye Diseases
Belgium, France, Spain, Italy, Germany
20/08/2026
Phase I/II
Phase I/II trial of Dinutuximab beta in combination with Irinotecan and Rapamycin in pediatric, adolescents and adult patients with relapsed/refractory bone tumors. BONE DINIRRA
2026-525463-40-00osteosarcomas, chondrosarcomas, Ewing sarcomas, Ewing-like …
DrugsDinutuximab Beta·Sirolimus·Irinotecan
Les Hopitaux Universitaires De Strasbourg
Neoplasms
France
20/08/2026
Phase IV
Effects of Menopausal Hormone Therapy on QTc in Genetically Confirmed Long QT Syndrome: A Prospective Randomized Sequential Crossover Study with Long-Term Observational Follow-Up (LQTS-HER)
2026-526442-28-00Long QT syndrome
DrugsEstradiol·Progesterone
Oslo Universitetssykehus HF
Cardiovascular Diseases
Norway
20/08/2026
Phase I/II
A Modular Open-label, Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Ascending Doses of AZD4956 as Monotherapy, and in Combination with Anti-Cancer Agents in Participants with Advanced/Metastatic Homologous Recombination Repair Defective Solid Tumours (PARTHENON)
2025-524171-22-00Solid Tumors
DrugSaruparib
AstraZeneca AB
Neoplasms
Spain
20/08/2026
Phase IV
An Open-Label Study to Investigate the Long-Term Effects of Acoramidis on Cardiac Function, Structure and Cardiac Amyloid Burden in Participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
2026-526068-19-00Transthyretin Amyloidosis
DrugAcoramidis
Eidos Therapeutics Inc.
Cardiovascular Diseases
Spain, Denmark
20/08/2026
Phase II
Treatment of post-traumatic stress disorder with medical nitrous oxide combined with exposure to a personal traumatic script: a multicenter randomized controlled trial (POTESTA)
2026-525826-39-00Post-Traumatic Stress Disorder
Centre Hospitalier Regional Universitaire De Tours
Mental Disorders
France
19/08/2026
Phase I
A clinical trial of MK-8210 in healthy participants (MK-8210-001)
2026-527022-13-00HIV-1 (Human Immunodeficiency Virus Type 1)
Merck Sharp & Dohme LLC
Virus Diseases
Belgium
19/08/2026
Phase III
JS2-MC-GZMI: A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm Study to Investigate the Efficacy and Safety of Adjunctive Treatment with Brenipatide in Delaying Time to Relapse Compared with Placebo in Adult Participants with Major Depressive Disorder (RENEW-MDD- 2)
2025-522310-24-00Depressive Disorder, Major
Eli Lilly & Co.
Mental Disorders
Poland, Greece, Spain, Germany
19/08/2026
Phase I
A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects with Metastatic Castration-Resistant Prostate Cancer
2026-526777-42-00Metastatic Castration-Resistant Prostate Cancer
Janux Therapeutics Inc.
Neoplasms
Spain
19/08/2026
Phase I/II
A Phase 1/2 Trial of TER-2013 in Patients with Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
2025-525036-34-00Solid Tumours
DrugsImlunestrant·Fulvestrant
Terremoto Biosciences Inc.
Neoplasms
Spain, Ireland, Hungary, Romania, France, Portugal, Belgium, Poland
18/08/2026
Phase III
Evaluation of an asPirin-free strategy with ticAgrelor in patieNTs witH a myocardial infarction treatEd medically alONe (PANTHEON)
2025-525159-20-00myocardial infarction
DrugsAcetylsalicylic acid·Ticagrelor
Montreal Heart Institute
Cardiovascular Diseases
France
18/08/2026
Phase III
A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rozanolixizumab in adult participants with ocular myasthenia gravis
2025-524756-54-00Ocular Myasthenia Gravis
DrugRozanolixizumab
UCB Biopharma
Immune System Diseases
Hungary, Greece, Italy, Spain, Germany, Poland, France
18/08/2026
Phase II
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial to Evaluate Safety, and Pharmacodynamics of Repeated Subcutaneously Administered RBD1119 in Participants with CAD
2026-525901-10-00Coronary artery disease
Ribocure Pharmaceuticals AB
Cardiovascular Diseases
Sweden, Poland
18/08/2026
Phase II
A Phase II, Randomized, Open-label, Multi-center Study of AK104 in Combination with Lenvatinib versus Lenvatinib in Participants with Advanced Hepatocellular Carcinoma Who Have Progressed on Atezolizumab and Bevacizumab
2025-524591-30-00Hepatocellular Carcinoma
Akeso Biopharma Co. Ltd.
Neoplasms
Poland, France, Spain, Italy
18/08/2026
Phase I
A study to test how well different and multiple doses of BI 3034701 are tolerated in people living with overweight or obesity
2026-526090-42-00overweight, obesity
Boehringer Ingelheim International GmbH
Nutritional and Metabolic Diseases
Germany
18/08/2026
Phase I
A clinical research study investigating how the body processes the new compound afabicin in people with kidney problems and people with normal kidney function
2026-526916-35-00Renal Impairment
Debiopharm International S.A.
Not possible to specify
Germany
18/08/2026
Phase II
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-7262 as Monotherapy and when Coadministered with Enlicitide Decanoate in Adults With Elevated Lipoprotein(a)
2025-525102-38-00Elevated lipoprotein(a)
Merck Sharp & Dohme LLC
Cardiovascular Diseases
Netherlands, Denmark, Germany, Spain
18/08/2026
Phase II
A Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 48-week SAR448851 treatment followed by open-label extension in participants with early Alzheimer’s disease.
2025-524581-14-00Dementia Alzheimer's type
Sanofi-Aventis Recherche & Developpement
Nervous System Diseases
Spain, Germany
18/08/2026
Phase III
Evaluation of the efficacy of intravenous lidocaine on chronic postoperative pain in patients requiring emergency abdominal surgery. Randomized, double-blind, controlled, multicenter study – LIDOC-POPEYE.
2025-523682-24-00emergency abdominal surgery
Centre Hospitalier Universitaire De Nantes
Anesthesia and Analgesia
France
17/08/2026
Phase II
FLUDARABINE-TREOSULFAN REDUCED INTENSITY CONDITIONING REGIMEN PRIOR HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST TRANSPLANTATION CYCLOPHOSPHAMIDE FOR OLDER AND/OR FRAIL PATIENTS WITH AML
2025-523632-39-00acute myeloid lymphoma
DrugsCiclosporin·Treosulfan·Mycophenolate Mofetil·Fludarabine
Institut Paoli Calmettes
Neoplasms
France
17/08/2026
Phase III
A Randomized, Double-masked, Comparative Clinical Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 938 8 mg Versus EYLEA® HD (Aflibercept) Delivered via Intravitreal Injection in Participants with Neovascular Age-related Macular Degeneration
2025-523500-72-00Neovascular Age-related Macular Degeneration (nAMD)
Amgen Inc.
Eye Diseases
Slovakia, Latvia, Czechia, Poland, Spain, Hungary, Lithuania
17/08/2026
Phase II
Efficacy of rituximab for remission maintenance in patients with primary angiitis of the central nervous system: an open-label, randomized, controlled trial comparing systematic rituximab infusions and azathioprine - MAINRIPAC
2026-525394-39-00Patients with primary angiitis of the central nervous system
DrugsAzathioprine·Rituximab
Groupe Hospitalier Universitaire Paris Psychiatrie Et Neuroscience
Nervous System Diseases
France
17/08/2026
Phase I
A clinical trial to learn about the effects of INR731 alone or with an androgen receptor pathway inhibitor (ARPI) in men with prostate cancer
2025-524080-20-00Metastatic castration resistant prostate cancer
Novartis Pharma AG
Neoplasms
France, Italy, Spain, Germany
17/08/2026
Phase III
Durvalumab after concurrent platinum/etoposide chemotherapy and high-dose twice-daily thoracic radiotherapy in limited stage small cell lung cancer – an open label, randomized phase III trial (DAHRTS)
2026-525513-31-00Small-cell lung cancer, limited stage
DrugDurvalumab
Norges Teknisk-Naturvitenskapelige Universitet NTNU
Neoplasms
Denmark, Finland, Estonia, Germany, Lithuania, Sweden, Norway, Netherlands
17/08/2026
Phase II
Effects of a CB1 Receptor Antagonist/Inverse Agonist (Rimonabant) on Walking Ability in Patients in the Chronic Phase of Stroke
2025-521693-33-00Stroke
Sinfatin S.L.
Nervous System Diseases
Spain
17/08/2026
Phase III
C4931007 - A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS
2025-523447-35-02Pneumoccoccal Immunisation
DrugPF-07872412
Pfizer Inc.
Bacterial Infections and Mycoses
Spain, Finland, Poland, Germany, Greece, Hungary, Italy
17/08/2026
Phase I/II
A Phase 1/2 Open-label, Multi-center Study to Evaluate the Safety and Clinical Activity of GSK5926371 in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas (B-NHL)
2025-524915-36-00Lymphoma, Non-Hodgkin
Glaxosmithkline Research & Development Limited
Neoplasms
Italy, Germany, Spain, Finland, France
17/08/2026
Phase III
A Phase III, Randomized, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer
2025-524445-27-00Metastatic castration-resistant prostate cancer (mCRPC)
DrugsBNT324·Prednisone·Docetaxel
BioNTech SE
Male Urogenital Diseases
Belgium, Spain, Italy, Poland, Germany, Hungary
17/08/2026
Phase I
A Two-part study to learn the amount of polymyxin E1 in the body over time formed after a single inhaled dose of colistimethate sodium (CMS) in healthy adults (Part 1) and after single inhaled and vein-infused doses of CMS in adults with non‑cystic fibrosis bronchiectasis (NCFB) (Part 2)
2025-524324-22-00Non-cystic fibrosis bronchiectasis
Zambon S.p.A.
Respiratory Tract Diseases
Belgium, Poland, Bulgaria
17/08/2026
Phase III
A Phase III Randomised, Double-Blind, Parallel-Group Study to Assess the Effect of Fixed Dose Combination Laroprovstat/Rosuvastatin Compared with Rosuvastatin on Low-Density Lipoprotein Cholesterol in Patients with Hypercholesterolaemia.
2026-526258-15-00Hypercholesterolaemia
DrugRosuvastatin
AstraZeneca AB
Nutritional and Metabolic Diseases
Germany
17/08/2026
Phase II
A phase IIa open-label dose-finding study with lead-in phase evaluating the safety, pharmacokinetics, and attenuating effects of trazodone on the consciousness-altering effects of psilocybin in individuals with Treatment-Resistant Depression
2025-523346-27-00Treatment-Resistant Depression
Universita' Degli Studi G. D'Annunzio Di Chieti
Mental Disorders
Italy
14/08/2026
Phase III
The HCC patient-journey study: a prospective, adaptive, master protocol, to assess the value of the available sequences of treatment for patients with advanced hepatocellular carcinoma. The Journey of liver cancer patient - J-LI
2026-525898-39-00Advanced hepatocellular carcinoma
DrugsSorafenib·Regorafenib·Tremelimumab·Cabozantinib
Azienda Sanitaria Locale Napoli 1 Centro
Neoplasms
Italy
14/08/2026
Phase II
Denosumab or Zoledronic acid for erosive hand osteoarthritis (EHOA) in patients with osteoporosis a randomized controlled trial (ZODIAC trial)
2026-526828-41-00Erosive hand osteoarthritis (EHOA)
DrugsZoledronic Acid·Denosumab
Azienda Ospedaliera Universitaria Integrata Verona
Musculoskeletal Diseases
Italy
14/08/2026
Phase II
A Phase 2, randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of CRD-4730 in patients with heart failure with reduced ejection fraction (HFREF) (CALIBRATE-HF)
2025-525033-31-00heart failure
DrugCRD-4730
Cardurion Pharmaceuticals Inc.
Cardiovascular Diseases
Latvia, Slovakia, Lithuania, Hungary, Italy, Netherlands, Spain, Poland, Bulgaria, Czechia
14/08/2026
Phase I
A study to test how BI 3034701 is taken up and processed by the body in healthy men with normal weight or overweight
2026-525825-19-00Healthy
Boehringer Ingelheim International GmbH
Not possible to specify
Hungary
14/08/2026
Phase I
Bioequivalence of Estradiol 10 mcg Vaginal Tablets in Healthy Women Participants.
2026-526477-42-00Not applicable (submitted trial is a bioavailability trial …
Laboratorios Leon Farma S.A.
Female Urogenital Diseases and Pregnancy Complications
Czechia
14/08/2026
Phase II
A Phase 2 Randomized Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Three Doses of Frevecitinib (KN-002) in Patients with Severe Asthma not Adequately Controlled with Medium to High Dose ICS/LABA Therapy (PANAIRAMA)
2023-509125-41-00Severe asthma
DrugSalbutamol
Kinaset Therapeutics Inc.
Respiratory Tract Diseases
Czechia, Bulgaria, Romania, Hungary, Germany, Poland, Greece
14/08/2026
Phase II
An Exploratory Phase 2 Multicenter, Double-blind, Randomized, Placebo controlled, Parallel Group Study to Investigate the Safety, Tolerability, and Efficacy of TML-6 in Early Alzheimer’s Disease
2026-525539-18-00Early Alzheimer’s Disease
Merry Life Biomedical Co. Ltd.
Nervous System Diseases
Sweden
14/08/2026
Phase I/II
An open-label phase I/II, single-center, interventional singlearm basket trial of UKT-CART19.1 in patients with relapsed/refractory autoimmune diseases
2024-519491-60-00ANCA associated vasculitis (AAV), Immune thrombocytopenic p…
Universitaetsklinikum Tuebingen AöR
Immune System Diseases
Germany
14/08/2026
Phase III
A Phase 3, Randomized, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Adults With Previously Untreated Primary Immune Thrombocytopenia (ITP)
2026-525454-11-00Diagnosis of primary ITP according to the 2019 Internationa…
DrugsRomiplostim·Prednisolone
Amgen Inc.
Hemic and Lymphatic Diseases
Spain, Hungary, Germany
14/08/2026
Phase II
TIPS : Immunomodulatory Treatment of Interstitial Lung Disease Associated with Surfactant related Gene Mutations
2026-525336-41-00Interstitial Lung Disease
DrugsAzithromycin·Hydroxychloroquine·Prednisolone·Prednisone
Assistance Publique Hopitaux De Paris
Respiratory Tract Diseases
France
14/08/2026
Phase II
[⁶⁸Ga]Ga-HKG301 PET/CT for staging and restaging patients with primary breast cancer: a phase II study (FAPILOUS)
2025-521324-29-00Primary breast cancer
Odense University Hospital
Neoplasms
Denmark
14/08/2026
Phase II
Quantitative Unified Assessment of Novel Triplet therapy and Unconventional Maintenance with Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer: A Phase II Pilot Trial
2026-525550-11-00Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
DrugXofigo
Alianza Multidisciplinar Para La Investigacion De Los Tumores Genitourinarios Guard
Male Urogenital Diseases
Spain
14/08/2026
Phase IV
Phase IV Low Intervention Clinical Trial to Study Biomarkers of "inflammageing" and Senescence in Pre-diabetic Patients Treated with Metformin: A Study nested within the project “NLRP3 Inflammasome at the Crossroad of Vascular Inflammageing: A Novel Target for Senomorphic Drugs”.
2026-527080-15-00Pre-diabetic Patients
Universidad Autonoma De Madrid
Metabolism
Spain
14/08/2026
Phase III
Phase II randomized trial evaluating modified FOLFIRINOX and FOLFOX in the treatment of locally advanced or metastatic small bowel adenocarcinoma [FIRE-12]
2025-524131-39-00locally advanced or metastatic small bowel adenocarcinoma
DrugsCalcium folinate·Irinotecan·Oxaliplatin
Charite Universitaetsmedizin Berlin KöR
Digestive System Diseases
Germany
13/08/2026
Phase I
A Phase 1b Study of ZN-c3 in Combination with Chemotherapy or Bevacizumab in Subjects with Ovarian, Peritoneal, or Fallopian Tube Cancer
2025-524868-38-00Ovarian, Peritoneal, or Fallopian Tube Cancer
K-Group Beta Inc.
Neoplasms
France
13/08/2026
Phase II
Multicenter, randomized, open-label non-inferiority trial, comparing two antibiotic therapy periods (3 versus 7 days) in patients with mild leptospirosis and seen at the hospital in 5 French overseas departments (Martinique, Guadeloupe, French Guiana, Reunion, Mayotte)
2024-518027-30-00leptospirosis
DrugDoxycycline
CHU De Martinique
Bacterial Infections and Mycoses
France
13/08/2026
Phase II
A TWO-STAGE, SINGLE-ARM, PHASE II STUDY OF ZONGERTINIB PLUS FULVESTRANT IN PARTICIPANTS WITH HORMONE RECEPTOR-POSITIVE/HER2-NEGATIVE ADVANCED BREAST CANCER HARBORING HER2 MUTATIONS (AGATHA)
2026-525328-10-00HR-positive/HER2-negative advanced breast cancer
DrugsZongertinib·Goserelin·Fulvestrant
Medica Scientia Innovation Research S.L.
Neoplasms
Spain, Italy, Germany
13/08/2026
Phase I/II
A two-part, randomised, double-blind, placebo-controlled, parallel-group, 12week trial investigating the safety, tolerability, pharmacokinetics and efficacy of XEN-D0501 in obese participants
2026-525869-42-00Obesity
Pila Pharma AB
Nutritional and Metabolic Diseases
Sweden
13/08/2026
Phase III
SERAFA-1: A Single arm, Open label, Multicentre, Phase IIIb Study Of Camizestrant plus Ribociclib in 1st line Treatment of ER-positive, HER2-negative Advanced Breast Cancer Patients
2025-523444-12-00Breast Cancer
DrugsCamizestrant·Ribociclib
AstraZeneca AB
Neoplasms
Poland, Spain, France, Germany, Italy
13/08/2026
Phase IV
A randomized, double blind, placebo-controlled study comparing the efficacy of dupilumab to standard of care (SOC) treatment following hospitalization for a COPD exacerbation
2025-524392-23-00Chronic obstructive pulmonary disease (COPD)
DrugDupilumab
Regeneron Pharmaceuticals Inc.
Respiratory Tract Diseases
Belgium, Italy, Spain
13/08/2026
Phase II
AN OPEN LABEL, SINGLE ARM, EXPLORATIVE TRIAL TO EVALUATE EFFICACY AND SAFETY OF BEROTRALSTAT IN PREVENTING ANGIOEDEMA ATTACKS IN SUBJECTS WITH ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE)
2025-524747-13-00Acquired angioedema due to C1 inhibitor deficiency
Policlinico San Donato S.p.A.
Genetic Phenomena
Italy
12/08/2026
Phase III
International, multicenter, blinded phase III clinical trial to assess the diagnostic efficacy of the skin prick test from ROXALL (SPT-RX) with different allergen extract solutions for in vivo diagnosis of IgE mediated allergies
2025-524676-32-00Patients suffering from rhinitis / rhinoconjunctivitis, wit…
ROXALL Medizin GmbH
Diagnosis
Germany, Spain
12/08/2026
Phase II
A RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, CLINICAL TRIAL OF COLCHICINE IN AMYOTROPHIC LATERAL SCLEROSIS (CO-ALS II)
2026-526460-20-00AMYOTROPHIC LATERAL SCLEROSIS
Azienda Ospedaliero Universitaria Di Modena
Musculoskeletal Diseases
Italy
12/08/2026
Phase I
Bioavailability Comparison of Finerenone 20 mg Tablets (Test vs. Comparator Product).
2026-527382-30-00Comparative bioavailability study under fasting conditions.
ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.
Cardiovascular Diseases
Czechia
12/08/2026
Phase II
A phase II, single arm two-phase, clinical study of individually adapted systemic radioligand therapy with 177Lu-PSMA I&T for patients with metastatic, castration-resistant prostate cancer
2026-527110-23-00Prostate cancer
Region Uppsala
Male Urogenital Diseases
Sweden
12/08/2026
Phase III
Prognostic value assessment of PSMA-T4 examination in the group of patients with triple-negative breast cancer (TNBC) qualified to radical therapy
2025-525110-29-01triple-negative breast cancer
Narodowe Centrum Badan Jadrowych
Neoplasms
Poland
12/08/2026
Phase II
Evaluation of the efficacy, safety, and tolerability of lutetium-177-labeled PSMA ligand in patients with progression of adenoid cystic carcinoma originating from the salivary glands - an open, non-commercial clinical trial
2026-525776-26-00adenoid cystic carcinoma of the salivary glands
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
Otorhinolaryngologic Diseases
Poland
12/08/2026
Phase I/II
Preventive Dendritic Cell vaccination for Lynch Syndrome (PREVENT-Lynch)
2025-524046-10-00Lynch Syndrome
Radboud universitair medisch centrum Stichting
Digestive System Diseases
Netherlands
12/08/2026
Phase I
A Study to Assess the Effects of Probenecid on the Pharmacokinetics of Mirdametinib and its Metabolites in Healthy Participants
2026-526403-30-00This clinical trial is performed in healthy participants; t…
Merck Healthcare KGaA
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Germany
12/08/2026
Phase III
Premedication with dexamethasone for preventing interstitial lung disease in patients with breast cancer treated with trastuzumab deruxtecan
2025-521798-15-00Breast Cancer
DrugDexamethasone
Istituto Di Ricerche Farmacologiche Mario Negri
Neoplasms
Italy
11/08/2026
Phase I
A dose escalation and expansion study of XB010 as a single agent and combination therapy in subjects with locally advanced or metastatic solid tumors
2025-524805-34-00Locally Advanced or Metastatic Solid Tumors
Exelixis Inc.
Neoplasms
Italy, Netherlands, France, Spain
11/08/2026
Phase I
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
2025-522532-14-00Advanced solid tumors
Pfizer Inc.
Neoplasms
Netherlands, France, Spain
11/08/2026
Phase IV
Patient-Controlled Anesthesia for endoscopic Procedural Sedation – PCAPS study
2025-524859-31-00Adenoma
DrugsAlfentanil·Midazolam·Propofol
Karolinska Institutet
Digestive System Diseases
Sweden
11/08/2026
Phase I/II
Bioequivalence clinical trial of two formulations of quetiapine.
2026-527162-72-00Healthy participants
Laboratorios Alter S.A.
Mental Disorders
Spain
11/08/2026
Phase III
A multicentre randomised study on percutaneous stellate ganglion block as first line treatment in patients with electrical storm: the STAR 2 study
2024-520387-34-01electrical storm
Fondazione IRCCS Policlinico San Matteo
Cardiovascular Diseases
Italy
11/08/2026
Phase II
Valproic acid and lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma
2026-525733-24-00Recurrent and/or Metastatic Adenoid Cystic Carcinom
DrugsSodium valproate·Lenvatinib
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
Neoplasms
Italy
11/08/2026
Phase II
SDH-FLUX - Development of a new biomarker for tumor development in patients with SDHx mutation by in vivo fluxomics
2023-506001-19-00paraganglioma or pheochromocytoma with surgical indication
Assistance Publique Hopitaux De Paris
Hormonal diseases
France
10/08/2026
Phase III
AVISO - Assessment of Flecainide versus Bisoprolol as First-Line Treatment for Premature Ventricular Contractions: a Multicenter Randomized Clinical Trial
2025-524584-20-00Premature ventricular contractions (PVC)
DrugsBisoprolol·Flecainide
Assistance Publique Hopitaux De Paris
Cardiovascular Diseases
France
10/08/2026
Phase II
A Phase 2 Multicentric Randomized Double-Blinded Efficacy and Safety Clinical Trial Comparing Several Doses of Aganirsen Eye Drops Emulsion to Extend Intravitreal Aflibercept Treatment Interval in Wet Age-Related Macular Degeneration (wAMD) Patients - SKY2 Study
2026-526775-27-00Wet Age-Related Macular Degeneration (wAMD) Patients
DrugAflibercept
Laboratoires Kol
Eye Diseases
France
10/08/2026
Phase I
A Phase 1, Open-Label, Multicenter Study of INCA036978 in Participants With Myeloproliferative Neoplasms
2026-525217-31-00Myeloproliferative Neoplasms
Incyte Corp.
Neoplasms
Italy, Belgium, Germany, France, Spain
10/08/2026
Phase I/II
Evaluation of Interference and Synergy of Anti-Circumsporozoite Antibodies on GA2-induced Immunity
2026-525353-37-00Plasmodium falciparum malaria
Leids Universitair Medisch Centrum (LUMC)
Parasitic Diseases
Netherlands
10/08/2026
Phase I
A research study looking into how a single dose of the medicine NNC0537-1482 moves through the body of participants with normal or reduced kidney function
2026-525271-57-00Heart failure with preserved ejection fraction
Novo Nordisk A/S
Cardiovascular Diseases
Germany
10/08/2026
Phase II
Effects of a CB1 Antagonist/Reverse Agonist (Rimonabant) on Functional Recovery in Stroke Patients During Subacute Phase.
2025-521689-86-00Stroke
Sinfatin S.L.
Nervous System Diseases
Spain
10/08/2026
Phase I
A Phase 1 Trial of GEN1119 in Participants with Solid Tumors
2026-525610-62-00Solid Tumors
Genmab A/S
Neoplasms
Spain, France
10/08/2026
Phase III
A single-arm, multicenter, phase III study to assess efficacy, pharmacokinetics, safety and tolerability of atrasentan in pediatric patients of 2 to <18 years of age with primary immunoglobulin A nephropathy (IgAN)
2025-522824-29-00Primary IgAN
DrugAtrasentan
Novartis Pharma AG
Immune system processes
France, Spain
10/08/2026
Phase I
Bioequivalence study 3 to compare pharmacokinetics of Parkinson´s disease drugs in healthy volunteers
2026-525450-11-00Parkinson's desease
Orion Corporation
Nervous System Diseases
Czechia
10/08/2026
Phase II
A Phase 2, Multicenter, Open-Label Study of Zolacabtagene Autoleucel (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants with Chronic Immune Thrombocytopenia (cITP) and Autoimmune Hemolytic Anemia (AIHA) (Breakfree-AiCE)
2025-524993-41-00Chronic Immune Thrombocytopenia (cITP) and Autoimmune Hemol…
Celgene Corp.
Immune System Diseases
Germany, Denmark
10/08/2026
Phase III
A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Monotherapy Study to Evaluate Efficacy of Roluperidone on Negative Symptoms in Adult Subjects with Schizophrenia, Followed by a 40-Week, Randomized, Double-Dummy Phase to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
2026-525925-19-00Schizophrenia with negative symptoms
DrugsAripiprazole·Risperidone·Olanzapine
Minerva Neurosciences Inc.
Mental Disorders
Bulgaria, Romania
10/08/2026
Phase III
Efficacy and safety of once daily oral semaglutide in adults with overweight or obesity
2025-524626-18-00Overweight and obesity
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Netherlands, Belgium, Greece, Poland, Spain, Denmark, France, Bulgaria, Sweden
10/08/2026
Phase IV
The RHINOME study
2026-527032-14-00Severe asthma
Region Hovedstaden
Respiratory Tract Diseases
Denmark
10/08/2026
Phase II
An Investigator-Initiated, Descriptive, Proof-of-Concept, Open-Label Pilot Study Focusing on Topical JAK Inhibition as a Novel Treatment of Cutaneous T-Cell Lymphoma
2025-523472-23-01Cutaneous T-cell lymphoma (CTCL) Mycosis fungoides
DrugDelgocitinib
Region Midtjylland
Therapeutics
Denmark
10/08/2026
Phase III
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves’ Disease Inadequately Controlled With Antithyroid Drugs
2025-523333-26-00Graves' Disease (GD)
Argenx
Hormonal diseases
Italy, Czechia, Spain, Denmark, Belgium, Romania, Latvia, France, Germany, Greece, Sweden, Poland, Lithuania, Bulgaria
07/08/2026
Phase III
Topical Clobetasol Propionate for Inflammatory Hand osteoarthritis: A randomized trial versus placebo.(PROCLAME)
2025-520678-20-00Adult patients with symptomatic and inflammatory Hand osteo…
DrugClobetasol Propionate
Assistance Publique Hopitaux De Paris
Musculoskeletal Diseases
France
07/08/2026
Phase IV
HORUS-Cytomegalovirus Open Proof-of-concept Exploratory trial
2025-524845-28-00Cytomegalovirus infection in solid-organ transplant recipie…
DrugEverolimus
Centre Hospitalier Universitaire Vaudois
Virus Diseases
France, Spain
07/08/2026
Phase IV
A Phase 4, Pragmatic, Randomized Trial to Evaluate the Effectiveness of An Influenza/COVID-19 Vaccine (mCombriax [mRNA-1083]) in Adults ≥ 65 Years (DAN-COMBO)
2026-526720-49-00Influenza infection, SARS-CoV-2 infection
Gentofte Hospital, Moderna Inc.
Virus Diseases
Denmark, Spain
07/08/2026
Phase I
A study in healthy men to test whether carbamazepine influences the amount of verducatib in the blood
2026-525821-19-00Healthy
Boehringer Ingelheim International GmbH
Not possible to specify
Germany
07/08/2026
Phase I
A study in healthy people to test how Zongertinib is taken up in the body when given as tablets made by two different manufacturers with or without food
2026-525696-77-00Healthy
Boehringer Ingelheim International GmbH
Not possible to specify
Germany
07/08/2026
Phase IV
CLINIC-CURE, a pilot exploratory clinical trial of analytical treatment interruption in people with HIV with a highly favorable profile
2026-526395-23-00HIV
DrugEmtricitabine
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
Virus Diseases
Spain
06/08/2026
Phase III
BETARGET : Randomized trial of individualizing BETA-lactam taRGET combining therapeutic drug monitoring, minimal inhibitory concentration and model-based dose adjustment, in Intensive Care Units patients with gram negative bacilli infection
2025-522819-42-01sepsis
DrugsCefotaxime·Ceftazidime·Meropenem·Amoxicillin
Centre Hospitalier Universitaire De Rennes
Bacterial Infections and Mycoses
France
06/08/2026
Phase II
[22961] A placebo-controlled, parallel-group, double blind, randomized, multi-cohort Phase 2 study to investigate efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of BAY 3670549 in adult participants with atrial fibrillation.
2025-523807-31-00Atrial fibrillation
Bayer AG
Cardiovascular Diseases
Belgium, Netherlands, Germany, Poland, Italy, Hungary, Bulgaria
06/08/2026
Phase I
A Randomized, Open label, Single Center, Single Oral Dose, Four Treatment, Four Period, Four Sequence, Crossover Bioavailability Study of Haleon Immediate Release Tablets 2X (paracetamol/naproxen 500 mg/125 mg) vs. Panadol Advance Tablets 2X (paracetamol 500 mg), Naprosyn Tablets 1X (naproxen 250 mg), administered individually in fasted conditions and Haleon Immediate Release Tablets 2X (paracetamol/naproxen 500 mg/125 mg) in fed conditions in Healthy Adult Participants
2025-524663-20-00Healthy volunteers, therapeutic indication not studied
Haleon CH SARL
Not possible to specify
Germany
06/08/2026
Phase III
Spironolactone and SGLT2 inhibitor to Address Fontan circulatory failure and Enhance Resilience: The SAFER-Fontan trial
2025-524783-38-00Fontan circulation
UZ Leuven
Cardiovascular Diseases
Belgium
06/08/2026
Phase I
A study in healthy people to compare how 2 different formulations of vicadrostat / empagliflozin tablets are taken up in the body
2025-524773-16-00Healthy
Boehringer Ingelheim International GmbH
Not possible to specify
Germany
06/08/2026
Phase IV
Influence of Doxycycline Use as Prophylaxis for Sexually Transmitted Infections on Bacterial Resistance and Gut Microbiota: MiDoxyR-PEP Study
2025-525150-19-01Colonization by methicillin-resistant S. aureus and gut mic…
Instituto De Investigacion Marques De Valdecilla
Bacterial Infections and Mycoses
Spain
06/08/2026
Phase I/II
Trial to study the safety, pharmacokinetics and preliminary antitumour activity of ODM-216 in patients with cancer
2026-525864-17-00Advanced solid tumours
Orion Corporation
Neoplasms
Spain
06/08/2026
Phase II
VIP-1 : Preclinical type 1 diabetes: the VIP-1 Study
2025-524318-27-00People with stage 1 or stage 2 T1D between the ages of 7 an…
DrugVerapamil
Assistance Publique Hopitaux De Paris
Immune System Diseases
France
05/08/2026
Phase III
A Phase 3, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Cabotegravir Ultra Long-acting Plus Rilpivirine Ultra Long-acting or Cabotegravir Long-acting Plus Rilpivirine Long-acting in Adults and Adolescents with HIV who are Virologically Suppressed on ART
2024-518511-19-00HIV Infections
Viiv Healthcare UK Limited
Immune System Diseases
Spain
05/08/2026
Phase I
An open label, randomized, single-dose, two-treatment, two-sequence, two-period, cross-over pilot comparative bioavailability study comparing Empagliflozin and Metformin f.c. tabs (12.5+1000) mg, VIANEX S.A., Greece versus Synjardy 12.5 mg/1,000 mg film-coated tablets, Boehringer Ingelheim International GmbH, Germany, in healthy male and female volunteers under fasting conditions.
2026-526397-17-00treatment of diabetes
Vianex S.A.
Hormonal diseases
Czechia
05/08/2026
Phase II
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study of YMI024 to assess efficacy in reducing inflammatory markers, safety, and tolerability in adults with stable coronary artery disease and elevated hsCRP
2026-525974-21-00Chronic Kidney Disease, Heart Failure, Coronary Artery dise…
Novartis Pharma AG
Cardiovascular Diseases
Germany
05/08/2026
Phase III
ROSY-F: Roll-Over Study for Participants Who Have Completed a Previous Study with Benralizumab (Fasenra) and Are Judged by the Investigator to Clinically Benefit from Continued Treatment
2025-523307-29-00Eosinophilic Granulomatosis with Polyangiitis (EGPA), Hyper…
DrugBenralizumab
AstraZeneca AB
Respiratory Tract Diseases
Denmark, Belgium, France, Italy, Netherlands, Austria, Poland
04/08/2026
Phase IV
A Phase IV, Randomized Controlled Trial to Evaluate the Effects of Resistance Training Versus Usual Care on Thigh Muscle Volume During Treatment with the Dual GIP/GLP-1 Receptor Agonist Tirzepatide in Adults with Obesity
2026-526200-69-00Obesity
Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)
Nutritional and Metabolic Diseases
Germany
04/08/2026
Phase II
A Phase IIb Study to Evaluate the Efficacy, Safety, and Tolerability of AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)) (ARGiNAUT)
2025-525016-41-00Idiopathic Pulmonary Fibrosis
AstraZeneca AB
Respiratory Tract Diseases
Poland, Hungary, Netherlands, Germany, Spain, Greece, Bulgaria, Italy, France, Denmark
04/08/2026
Phase III
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared with Placebo in Adults with Type 2 Diabetes Mellitus on Background Insulin (Eluminate-3)
2025-523935-20-00type 2 diabetes mellitus
DrugElecoglipron
AstraZeneca AB
Nutritional and Metabolic Diseases
Poland, Germany, Bulgaria, Czechia
04/08/2026
Phase I
Study in healthy volunteers to evaluate how the body processes Iadademstat and if food affects it
2026-525953-35-00Healthy Volunteers
Oryzon Genomics S.A.
Not possible to specify
Spain
04/08/2026
Phase I
A study of enzomenib investigating potential drug-drug interactions and the effect of liver impairment in adult patients with advanced cancer
2025-524652-63-00Advanced Cancer
Sumitomo Pharma America Inc.
Neoplasms
Spain, Bulgaria, Poland, Romania
04/08/2026
Phase III
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron compared with Placebo in Adults with Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin (Eluminate-4)
2025-523940-12-00type 2 diabetes mellitus
AstraZeneca AB
Nutritional and Metabolic Diseases
Germany, Bulgaria, Spain, Denmark
03/08/2026
Phase III
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron and Dapagliflozin in Combination, Compared with Elecoglipron Alone and Dapagliflozin Alone, in Adults with Type 2 Diabetes Mellitus (Eluminate-5)
2025-523941-81-00type 2 diabetes mellitus
AstraZeneca AB
Nutritional and Metabolic Diseases
Slovakia, Poland, Czechia, Germany, Hungary, Greece, Denmark
03/08/2026
Phase IV
Non-inferiority of surgical treatment of cartilage defects of the knee with autologous minced cartilage implantation (AMCI) and matrix-asscociated autologous chondrocyte implantation with respect to KOOS at 24 months (M ACI) - MinCaRCT
2026-526179-49-00Full-thickness cartilage defects of the knee
Medical Center - University Of Freiburg
Musculoskeletal Diseases
Germany
03/08/2026
Phase III
RUBY study « Randomized controlled trial testing the efficacy of corticosteroid therapy versus placebo in fibrotic hypersensitivity pneumonitis.»
2025-521591-64-00Adult patients with a diagnosis of fibrotic Hypersensitivit…
Assistance Publique Hopitaux De Paris
Respiratory Tract Diseases
France
03/08/2026
Phase III
A Randomized Phase 2/3 Study Evaluating the Safety and Efficacy of Pivekimab Sunirine (PVEK) in Combination with Venetoclax and Azacitidine in Adult Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible to Receive Intensive Chemotherapy
2025-523724-47-00Acute Myeloid Leukemia
DrugsPivekimab Sunirine·Azacitidine·Venetoclax
AbbVie Deutschland GmbH & Co. KG
Neoplasms
France, Austria, Spain
03/08/2026
Phase I
A First-in-Human Study of INCA035784 in Participants With Myeloproliferative Neoplasms
2026-525360-18-00Myeloproliferative Neoplasms
Incyte Corp.
Neoplasms
Italy, Belgium, Germany
03/08/2026
Phase III
A double-blind, randomised, placebo-controlled trial evaluating the efficacy and safety of oral nerandomilast treatment in patients with systemic sclerosis (SSc)
2025-523884-39-00Systemic sclerosis
DrugNerandomilast
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Skin and Connective Tissue Diseases
Denmark, Hungary, Sweden, Netherlands, Germany, Belgium, France, Greece, Norway, Finland, Czechia, Portugal, Bulgaria, Spain, Austria, Romania, Croatia, Poland, Estonia, Italy, Lithuania
03/08/2026
Phase II
Pharmacodynamic Evaluation of OV329 in Participants with Epilepsy and a Photo-Induced Generalized Epileptiform EEG-Response Phase 2 Proof-of-Concept.
2026-527114-23-00Epilepsy
Ovid Therapeutics Inc.
Nervous System Diseases
Netherlands
03/08/2026
Phase I
Treatment of patients with autoantibody-positive autoimmune diseases and severe interstitial lung fibrosis with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector - a single center Phase I/II clinical trial (HD-CAR-ILD-1)
2024-519592-26-00Therapy-resistant and progressing lung fibrosis in the cour…
Universitaetsklinikum Heidelberg AöR
Immune System Diseases
Germany
03/08/2026
Phase III
A Phase 3, Randomized, Double-blind, and Active‑controlled Multicenter Study to Evaluate the Efficacy and Safety of JNJ‑78934804 in Participants With Moderately to Severely Active Crohn’s Disease
2026-525922-39-00Moderately to Severely Active Crohn’s Disease
Janssen Cilag International
Immune System Diseases
Norway, Romania, Austria, Italy, Slovakia, Germany, Hungary, Netherlands, Belgium, France, Portugal, Czechia, Poland, Spain, Greece
03/08/2026
Phase III
A Phase 3 Randomized, Double-blind, and Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants with Moderately to Severely Active Ulcerative Colitis
2026-525923-26-00Moderately to Severely Active Ulcerative Colitis
DrugsJNJ-78934804·Guselkumab
Janssen Cilag International
Immune System Diseases
France, Bulgaria, Romania, Slovakia, Norway, Denmark, Greece, Italy, Austria, Poland, Netherlands, Czechia, Germany, Belgium, Spain, Hungary, Portugal
03/08/2026
Phase I
A Phase I Study to Evaluate ELA822
2025-524911-34-00Healthy Volunteers
Electra Therapeutics Inc.
Immune System Diseases
Austria
02/08/2026
Phase II
Botulinum toxin A in the Treatment of Chronic Postsurgical Pain in Lung Cancer Patients: A feasibility study
2026-525669-33-00Chronic postsurgical pain (CPSP)
DrugXeomin
Aalborg University Hospital
Therapeutics
Denmark
01/08/2026
Phase II
The Danish Anorexia Nervosa Psilocybin RCT (DANP-RCT). A Randomised, Active-Placebo-Controlled, Triple-blind, Superiority Study of Psilocybin-Assisted Acceptance and Commitment Therapy (ACT) in the Treatment of Treatment-resistant Anorexia Nervosa.
2025-524939-39-02Anorexia nervosa
DrugPsilocybin
Slagelse Hospital
Mental Disorders
Denmark
01/08/2026
Phase I
A Randomised, Placebo‑Controlled Trial to Assess Effect of IMU‑838 on QT/QTc
2026-526859-54-00Multiple sclerosis
Immunic AG
Nervous System Diseases
Belgium
31/07/2026
Phase I
A study to test how well different doses of BI 3822971 are tolerated by people with advanced cancer (solid tumours)
2026-525785-22-00solid tumours
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Neoplasms
Spain
31/07/2026
Phase III
Perioperative Intravenous Metamizole in Laparoscopic Cholecystectomy: A rondomized, double blind, clinical trial.
2026-526531-18-00Post operative pain relief in Patients undergoing laparosco…
UZ Leuven
Anesthesia and Analgesia
Belgium
31/07/2026
Phase II
An Open-Label Phase IIa Trial Exploring the Safety, Tolerability, and Efficacy of the T Cell Engager OM336 for Desensitization of Kidney Transplant Candidates
2025-523222-40-00End stage renal failure
DrugsDiphenhydramine·Paracetamol·Dexamethasone
Medical University Of Vienna
Pathological Conditions, Signs and Symptoms
Austria
31/07/2026
Phase II
A Multicenter, Open-Label, Long-Term, Safety and Tolerability Extension Study of PTI5803 as adjunctive therapy in patients ≥ 14 years of age with drug-resistant seizures associated to focal cortical dysplasia.
2026-525161-40-00Drug resistant focal epilepsy related to focal cortical dys…
DrugPTI5803
PannTheraPi
Nervous System Diseases
France
31/07/2026
Phase I
Whole body HER2 quantification with 89Zr-Trastuzumab PET/CT to asses Zr-trastuzumab accumulation in HER2-mutated and HER2-overexpressing metastatic non-small cell lung cancer
2026-525568-17-00HER2 mutation positive NSCLC
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Pathological Conditions, Signs and Symptoms
Netherlands
30/07/2026
Phase I/II
A Phase 1b/2a first-in-human, multicentre, randomized, double-blind, placebo-controlled study of multiple ascending dose (Part1) followed by an open-label extension (Part2) to assess the safety, tolerability, and pharmacokinetics of intrathecally administered S233107 in participants with spinocerebellar ataxia type 3
2025-525111-17-00Spinocerebellar ataxia type 3
Institut De Recherches Internationales Servier IRIS
Nervous System Diseases
France, Denmark, Spain, Portugal
30/07/2026
Phase I
Nav 1.8 and 1.7 combo trial
2026-526867-39-00Pain
Niroda Therapeutics Inc.
Nervous System Diseases
Netherlands
30/07/2026
Phase I
Bioequivalence of Tramadol retard 200 mg Prolonged-Release Tablets in Healthy Participants Under Fasting Conditions
2026-525836-41-00Not applicable (submitted trial is a bioavailability trial …
Laboratorios Cinfa S.A.
Nervous System Diseases
Czechia
30/07/2026
Phase III
J3L-MC-EZEJ: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Lepodisiran to Investigate the Effect on Coronary Plaque in Adults With Elevated Lp(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event
2025-524858-34-00Lipoprotein(a), Atherosclerosis, Cardiovascular Diseases
Eli Lilly & Co.
Cardiovascular Diseases
Hungary, Czechia, Spain, Netherlands
30/07/2026
Phase I
Study to assess the plasma concentration of rilzabrutinib given as a tablet to adult participants with severe renal impairment compared to matched participants with normal renal function
2026-525707-27-00Renal Impairment
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Germany
30/07/2026
Phase III
A Phase III, Multicentre, Randomised, Open-label Study to Compare the Efficacy and Safety of AZD0486 plus Rituximab versus Chemotherapy plus Rituximab in Previously Untreated Participants with Follicular Lymphoma (SOUNDTRACK-F1)
2023-510098-33-01Follicular Lymphoma
DrugsSurovatamig·Bendamustine·Vincristine·Doxorubicin
AstraZeneca AB
Neoplasms
Denmark, Germany
29/07/2026
Phase I
A Phase 1a/1b, multicenter, open-label study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of PLN-101095 alone and in combination with pembrolizumab in adults with advanced or metastatic solid tumors following progression on immune checkpoint inhibitor therapy
2026-526116-36-00Advanced or metastatic solid tumours
Pliant Therapeutics Inc.
Neoplasms
Spain
29/07/2026
Phase III
B-HAPPI: Bipolar disorder and high-dose adjunctive pramipexole for anhedonic depression – a phase III, double-blind, randomized controlled trial
2026-526383-20-00Bipolar disorder
Region Skane
Mental Disorders
Sweden
29/07/2026
Phase I/II
A Phase I/II, randomized, placebo-controlled, multi-arm, dose-finding study to evaluate the safety, efficacy and immunogenicity of an Acne mRNA vaccine candidate in adults with moderate to severe acne 18 to 45 years of age
2025-521740-38-00Acne
DrugAcne mRNA vaccine
Sanofi Pasteur Inc.
Skin and Connective Tissue Diseases
Spain, Germany, Poland
29/07/2026
Phase IV
Effectiveness of Trazodone on Emotional Blunting in Patients with Major Depressive: a Phase IV, Open-label, clinical study
2025-523267-38-00Major depressive disorder (MDD)
Angelini Pharma Italia Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. Enunciabile Anche Angelini Pharma Italia S.p.A. Angelini Pharma S.p.A. A.C.R.A.F. S.p.A. Acraf S.p.A. Angelini S.p.A. aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.
Mental Disorders
Bulgaria, Poland, Hungary
29/07/2026
Phase III
A Phase III, Randomized, Double-blind, Parallel-group, Placebo controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants with HFpEF and HFmrEF (Elevate-HF)
2026-526304-79-00Heart failure with preserved ejection fraction (HFpEF) and …
DrugsElecoglipron·Dapagliflozin
AstraZeneca AB
Cardiovascular Diseases
Spain, Hungary, Germany, Poland, Italy, Bulgaria, Netherlands, Austria, Romania, Sweden, France, Greece, Slovakia, Czechia
29/07/2026
Phase I
An Open-label Phase 1 Study in Healthy Adult Participants to Investigate the Effect of Itraconazole on the Blood Levels of Engasertib
2026-526311-11-00This clinical trial is performed in healthy participants; t…
Vaderis Therapeutics AG
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Germany
29/07/2026
Phase II
A Phase 2 Study of Alisertib in Combination with Paclitaxel in Patients with Small Cell Lung Cancer
2026-525382-47-00Small Cell Lung Cancer (SCLC)
DrugPaclitaxel
Puma Biotechnology Inc.
Neoplasms
France, Poland, Spain
28/07/2026
Phase I/II
Melanoma-TBK1-inhibitor enhanced Immuno Therapy with Checkpoint Inhibitors: a Phase IB/II Trial in Unresectable Stage III or Stage IV Cutaneous Melanoma
2026-526821-16-00Unresectable Stage III or Stage IV Cutaneous Melanoma
DrugsNivolumab·Pembrolizumab
Karolinska University Hospital
Neoplasms
Sweden
28/07/2026
Phase IV
Comparative study of two vaccination schedules for the subunit Herpes Zoster vaccine in Multiple Sclerosis and Neuromyelitis optica spectrum disease patients treated with anti-CD20 therapy: an open-label randomised controlled trial.
2025-525106-37-00Multiple Sclerosis and Neuromyelitis optica spectrum
DrugsOcrelizumab·Rituximab
Centre Hospitalier Universitaire De Toulouse
Nervous System Diseases
France
28/07/2026
Phase II
OBINUSS - Safety and efficacy of obinutuzumab in systemic sclerosis: a phase II, randomized, double-blinded versus placebo-controlled trial
2025-524003-68-00Patients with newly or active diffuse Systemic sclerosis at…
DrugObinutuzumab
Assistance Publique Hopitaux De Paris
Immune System Diseases
France
28/07/2026
Phase IV
STRategiEs for Antiplatelet Management foLlowIng acute coroNary syndromE (STREAMLINE)
2026-525933-22-00ischemic heart disease
DrugsPrasugrel·Acetylsalicylic acid·Ticagrelor
Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz
Cardiovascular Diseases
Spain, Norway
28/07/2026
Phase I
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination with Bevacizumab in Adult Participants with Ovarian Cancer
2025-522209-40-00Ovarian Cancer
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Portugal, Denmark, Spain, France
27/07/2026
Phase I
A Phase 1 Study of PRT12396 in Participants with Select Myeloproliferative Neoplasms
2026-525484-40-00Post-Essential Thrombocythemia Myelofibrosis, Post-Polycyth…
Prelude Therapeutics Inc.
Neoplasms
Italy, France, Spain
27/07/2026
Phase III
A Randomized Controlled Study Evaluating Short-Term Dual Antiplatelet Therapy with Low-Dose Ticagrelor (60 mg) Followed by Monotherapy versus Standard-Duration Dual Antiplatelet Therapy with Clopidogrel in Patients with Chronic Coronary Syndrome Undergoing Percutaneous Coronary Intervention: the STELAR trial
2026-526368-18-00Chronic Coronary Syndrome in patients undergoing percutaneo…
DrugClopidogrel
Azienda Ospedaliera Universitaria Gaetano Martino Messina
Cardiovascular Diseases
Italy
27/07/2026
Phase I
A first-in-human, randomized, double-blind, placebo-controlled, 3-part study assessing the safety, tolerability, pharmacodynamics and pharmacokinetics of GL0071 after single and repeated ascending subcutaneous doses in healthy normal weight, overweight and obese participants, as well as a 12-week treatment randomized, double blind, placebo-controlled exploratory Proof-of-Concept study in overweight and obese participants.
2025-524233-45-00Type 2 diabetes mellitus, Overweight
Sun Pharmaceutical Industries Limited
Nutritional and Metabolic Diseases
Belgium
27/07/2026
Phase II
A Cancer Research UK Phase II trial of CY-101 given via intratumoural administration in locally advanced or metastatic adrenocortical carcinoma (CLARITY)
2025-522757-19-00LOCALLY ADVANCED OR METASTATIC ADRENOCORTICAL CARCINOMA
Cancer Research UK
Neoplasms
Spain, France, Germany, Norway
27/07/2026
Phase II
A Phase 2 Study Evaluating the Safety and Efficacy of Neoadjuvant Amivantamab in Combination with Lazertinib or Chemotherapy in Resectable EGFR-Mutated Non-Small Cell Lung Cancer
2025-524816-13-00Non-small Cell Lung Cancer
DrugsLazertinib·Amivantamab
Janssen Cilag International
Neoplasms
Spain
27/07/2026
Phase III
A clinical study to compare efficacy and safety of two different doses of CagriSema and semaglutide in participants with obesity with or without type 2 diabetes
2025-522488-14-00Participants with obesity with or without type 2 diabetes
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Greece, Portugal, France, Slovakia, Bulgaria, Netherlands, Romania, Italy, Austria, Poland, Hungary, Spain, Czechia, Belgium
27/07/2026
Phase III
4TAZPower: A Phase 3b/4, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Patients with Genetically Confirmed Barth Syndrome
2025-523837-25-00Barth Syndrome
DrugElamipretide
Stealth Biotherapeutics Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Ireland, Netherlands, France, Italy
27/07/2026
Phase I/II
Phase I/II Trial to Determine Safety and Efficacy of non-Viral Allogeneic Dual CD123/33-Chimeric Antigen Receptor CIK (CARCIK-CD123/33) Cells in Adult and Pediatric Patients with Relapse/Refractory Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
2025-524977-18-00Acute myeloid leukemia and Blastic plasmacytoid dendritic c…
Fondazione Tettamanti, Fondazione IRCCS San Gerardo Dei Tintori
Neoplasms
Italy
27/07/2026
Phase I
A clinical trial of MK-3868 in healthy participants (MK-3868-001)
2026-526674-17-00Malaria
Merck Sharp & Dohme LLC
Parasitic Diseases
Belgium
27/07/2026
Phase III
A Phase 3 Randomized, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV-706 versus Standard of Care in Subjects with Relapsed/Refractory Small Cell Lung Cancer (SCLC)
2025-523819-11-00Small Cell Lung Cancer
DrugsABBV-706·Topotecan
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Italy, Greece, Spain, Belgium, France, Austria, Germany
27/07/2026
Phase III
Multi-Center, Placebo-Controlled, Phase 3 Study of Etripamil Nasal Spray (NS) in Patients with Atrial Fibrillation and Rapid Ventricular Rate (RVR). The ReVeRA-301 Trial.
2024-516251-40-01Atrial Fibrillation
Milestone Pharmaceuticals Inc.
Cardiovascular Diseases
Netherlands
27/07/2026
Phase IV
Within-Patient Comparison of Serum Transthyretin Response to Tafamidis Versus Acoramidis: A Pilot Crossover Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
2026-526526-41-01Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
DrugAcoramidis
Medical University Of Vienna
Cardiovascular Diseases
Austria
27/07/2026
Phase IV
Thromboprophylaxis with apixaban during neoadjuvant therapy for muscle-invasive bladder cancer (ACB): An international randomized controlled trial evaluating apixaban versus no anticoagulation in patients scheduled to undergo radical cystectomy or chemoradiotherapy for muscle-invasive bladder cancer
2024-518861-90-00Venous thromboembolism (in bladder cancer patients)
DrugApixaban
HUS-Yhtymae
Therapeutics
Finland
27/07/2026
Phase I
A study in healthy people to measure how different doses of verducatib affect the heart
2026-525813-30-00Healthy volunteer trial
Boehringer Ingelheim International GmbH
Not possible to specify
Germany
27/07/2026
Phase III
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Master Protocol to Evaluate the Efficacy and Safety of Elecoglipron in Participants with Obesity or Overweight with or without Type 2 Diabetes Mellitus (Embold)
2025-524688-19-00Participants Living with Obesity or Overweight with at leas…
AstraZeneca AB
Nutritional and Metabolic Diseases
Spain, Germany, Italy, Poland
27/07/2026
Phase III
An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients with Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease
2025-523960-19-00Advanced or Metastatic HR+/HER2- Breast Cancer
BeOne Medicines I GmbH
Neoplasms
Poland, Italy, Germany, France, Spain
27/07/2026
Phase II
Evaluation of the effect of botulinum toxin on refractory upper limb rest tremor in parkinsonian patients, double-blind, placebo-controlled cross-over study : TOX PARK
2026-525862-23-00parkinson disease
DrugsDysport·NaCl
Centre Hospitalier Universitaire De Toulouse
Nervous System Diseases
France
24/07/2026
Phase II
DECREASE-IPC 2025-068 : De-Ecalating neoadjuvant Chemoimmunotherapy in early triple-negative BREASt cancer
2025-525040-18-00triple‑negative breast cancer
DrugsEndoxan·Paclitaxel·Pembrolizumab
Institut Paoli Calmettes
Neoplasms
France
24/07/2026
Phase II
functional imaging of digital osteoarthritis and rheumatoid arthritis using 99mTc-NTP15-5 in nuclear medicine : phase II clinical study
2025-523650-14-00Arthritis rheumatoid and finger osteoarthritis
Centre Jean Perrin
Not possible to specify
France
24/07/2026
Phase IV
VATS or Intrapleural Enzymatic Therapy for patientS with empyema (the VIETS trial)
2026-526289-25-00Parapneumonic pleural infection/pleural empyema
DrugsDornase Alfa·Alteplase
Amsterdam UMC Stichting
Therapeutics
Netherlands
24/07/2026
Phase I
Immune Cell Therapy for People with Early, Active Multiple Sclerosis
2025-522409-39-00Newly diagnosed highly-active Multiple Sclerosis
Medizinische Hochschule Hannover
Nervous System Diseases
Germany
24/07/2026
Phase III
An Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Salanersen (BIIB115) in Participants Aged 15-60 Years With Spinal Muscular Atrophy Who Are Either Treatment-Naïve or Have Previously Been Treated With Risdiplam
2025-524054-34-00Spinal Muscular Atrophy
DrugSalanersen
Biogen Idec Research Limited
Nervous System Diseases
Finland, Spain, Italy, Poland, Ireland, Germany, France
24/07/2026
Phase II
A randomised active-controlled trial to assess the safety and pharmacodynamics of two blinded doses of vortosiran and open-label apixaban in patients with non-valvular atrial fibrillation
2026-525417-31-00non-valvular atrial fibrillation
DrugsRBD4059·Apixaban
Ribocure Pharmaceuticals AB
Cardiovascular Diseases
Norway, Denmark, Poland, Sweden
24/07/2026
Phase III
A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Renal Outcomes and Mortality in Participants with Chronic Kidney Disease (Elevate-CKD)
2025-523994-41-00Chronic kidney disease (CKD) in adults, with specified rang…
DrugsElecoglipron·Dapagliflozin
AstraZeneca AB
Cardiovascular Diseases
Czechia, Italy, Hungary, Romania, Bulgaria, Sweden, Denmark, Poland, Spain, Norway, Finland, Greece, France, Germany
24/07/2026
Phase III
Phase 3 Randomized Study of Teclistamab and Talquetamab (Tec-Tal) Versus Daratumumab and Lenalidomide (DR) in Minimal Residual Disease (MRD) Positive Patients With Newly Diagnosed Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation (TiTan)
2025-525097-11-00Multiple myeloma
DrugsTalquetamab·Teclistamab·Daratumumab·Lenalidomide
Polish Myeloma Consortium
Hemic and Lymphatic Diseases
Poland
23/07/2026
Phase I
A Study to Evaluate the Safety and Activity of an Inhaled Investigational Drug (RO7616605) in Healthy Volunteers and Participants With COPD
2025-525042-22-00Chronic Obstructive Pulmonary Disease (COPD) and Chronic Br…
Genentech Inc.
Respiratory Tract Diseases
Germany
23/07/2026
Phase II
Immune dynamics and biomarkers of anti-tumor response in BMS-986340 (anti-CCR8) and nivolumab (anti-PD-1) co-treatment of metastatic tumors
2025-524125-40-01Metastatic solid tumors, with the following specific indica…
DrugNivolumab
Humanitas Mirasole S.p.A., Fondazione Humanitas Per La Ricerca Ets
Neoplasms
Italy
23/07/2026
Phase II
A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of SIR9900 in Patients with VEXAS Syndrome (SIVEX)
2025-524918-28-00VEXAS Syndrome
Sironax USA Inc.
Immune System Diseases
Italy
23/07/2026
Phase II
IKF-099/D-FLOT-TNT Total Neoadjuvant Treatment with preoperative FLOT/Durvalumab plus postoperative Durvalumab for Resectable Gastroesophageal Adenocarcinoma
2026-525185-21-00Gastroesophageal Adenocarcinoma
Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
Digestive System Diseases
Germany, Spain
23/07/2026
Phase III
A Phase 3b, Open-Label Study of Crinecerfont to Evaluate Androgen Reduction and Related Outcomes in Adults With Classic Congenital Adrenal Hyperplasia
2025-524282-24-00Classic Congenital Adrenal Hyperplasia (CAH)
DrugCrinecerfont
Neurocrine Biosciences Inc.
Hormonal diseases
Czechia, Germany, Sweden, Portugal, Romania, Bulgaria, Italy, Austria, Spain
23/07/2026
Phase III
Prospective, multicentre, open-label, single arm trial on contraceptive efficacy, safety and tolerability of LPRI-CF113 (Drospirenone 4 mg + 2.8 mg) during 13 cycles.
2026-525727-24-00No medical condition
Chemo Research S.L.
Not possible to specify
Sweden, Czechia, Spain, Hungary, Poland, Finland, Romania
23/07/2026
Phase III
A Phase 2/3 Randomized, Double Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants with Huntington’s Disease
2025-522263-14-00Huntington’s Disease
DrugSKY-0515
Skyhawk Therapeutics Inc.
Nervous System Diseases
Germany, Spain
23/07/2026
Phase I/II
A Phase 1/2, dose escalation and expansion study of TRI-611, an oral ALK molecular glue degrader in participants with advanced ALK-positive NSCLC
2025-524418-27-00Advanced ALK-positive NSCLC
Triana Biomedicines Inc.
Respiratory Tract Diseases
France, Italy, Germany, Spain
22/07/2026
Phase I
An unblinded, single arm, pilot observational study to test the safety, tolerability, immunogenicity and the biological effects of TRB-001 vaccination in individuals who have previously undergone aSyn immunotherapy
2026-526294-42-00Parkinson's disease
Tridem Bioscience FlexCo
Nervous System Diseases
Austria
22/07/2026
Phase IV
Real-World Effectiveness of the Adjuvanted RSVPreF3 Vaccine in Adults ≥60 Years: A Pragmatic Randomized Trial (BronquiVal)
2026-526804-59-00Respiratory syncytial virus infection–related respiratory d…
Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana
Respiratory Tract Diseases
Spain
22/07/2026
Phase III
Colchicine for the Reduction of Dependency and Vascular Events after an Acute Intracerebral Hemorrhage (CoVasc-ICH2)
2025-523435-18-00Major cardiovascular events (MACE), spontaneous intracerebr…
Hamilton Health Sciences Corporation, PHRI Population Health Research Institute International
Cardiovascular Diseases
Spain, Belgium
22/07/2026
Phase IV
Do GLP-1 based therapies improve the immunological response to vaccination in diabetes?
2026-525909-13-00Diabetes
DrugsPneumococcal Vaccine·Liraglutide
Radboud universitair medisch centrum Stichting
Immune System Diseases
Netherlands
22/07/2026
Phase II
Local and systemic immune modulation by Rilvegostomig (AZD2936) in the treatment of advanced gastric cancer (RILVE Project)
2026-525620-23-00advanced gastric cancer
DrugsRilvegostomig·Pembrolizumab
Vall D Hebron Institute Of Oncology
Neoplasms
Spain
22/07/2026
Phase I
Tarlatamab Before and After Surgery for Recurrent High-Grade Glioma
2025-524359-30-00surgically resectable recurrent high-grade glioma
Vall D Hebron Institute Of Oncology
Neoplasms
Spain
22/07/2026
Phase I/II
A Phase 1/2a, Open-label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BMS-986528 in Participants with Refractory Rheumatoid Arthritis
2025-520666-22-00Refractory, difficult-to-treat Rheumatoid Arthritis
DrugTocilizumab
Bristol-Myers Squibb Services Unlimited Company
Immune System Diseases
Poland, Italy, Spain, Germany
22/07/2026
Phase III
A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared with Oral Semaglutide in Adults with Type 2 Diabetes Mellitus (Eluminate-2)
2025-523933-24-00type 2 diabetes mellitus
AstraZeneca AB
Nutritional and Metabolic Diseases
Poland, Hungary, Italy, Bulgaria, Germany
22/07/2026
Phase II
A Phase 2, Multicenter, Randomized, Double-blind, Placebocontrolled Study, to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered Mivelsiran in Adult Participants with Early-Stage Down Syndrome-Associated Alzheimer’s Disease (DS-AD)
2025-523390-42-00Early-Stage Down Syndrome-Associated Alzheimer’s Disease (D…
DrugMivelsiran
Alnylam Pharmaceuticals Inc.
Nervous System Diseases
Italy, Netherlands, Spain, Germany, Ireland
22/07/2026
Phase I
Phase 1/1b Study of BMS-986463 in Advanced Malignant Tumors
2025-523067-38-01Advanced Malignant Tumors; High-grade Serous Ovarian Carcin…
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Spain, France, Italy
21/07/2026
Phase III
A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis
2026-525242-29-00Primary Sclerosing Cholangitis
DrugElafibranor
Ipsen Bioscience Inc.
Digestive System Diseases
Spain, Sweden, Germany, Romania, Finland, Portugal, Austria, Italy, Denmark, Czechia, France, Netherlands, Poland, Belgium, Norway
21/07/2026
Phase II
Randomized Controlled Trial Assessing the Effectiveness and Safety of Fecal Microbiota Transfer for VRE Eradication in Immunocompromised Patients (EU CTR, Phase II) – VRE-ex
2026-525632-41-00Intestinal colonization with vancomycin-resistant enterococ…
Fraunhofer Institute For Translational Medicine And Pharmacology ITMP
Bacterial Infections and Mycoses
Germany
21/07/2026
Phase I/II
A Phase 1/2 First-Time-in-Human, open-label, multicenter, dose escalation and dose optimization study of GSK5471713 in adult participants with metastatic castration resistant prostate cancer (mCRPC).
2025-523874-17-00Neoplasms, Prostate
Glaxosmithkline Research & Development Limited
Neoplasms
Netherlands, France, Spain
21/07/2026
Phase I
A more sustainable perioperative treatment regimen for gastroesophageal cancer —replacing 5-FU with capecitabine within the FLOT regimen
2026-526209-13-00Gastric Cancer, Esophageal cancer
DrugCapecitabine
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Neoplasms
Netherlands
21/07/2026
Phase II
A Phase 2, open-label, randomized, dose optimization study evaluating the efficacy and safety of belantamab mafodotin administered in combination with cyclophosphamide, bortezomib, and dexamethasone in adult participants with newly diagnosed amyloid light chain amyloidosis (ALANIS)
2025-522803-60-00newly diagnosed amyloid light chain amyloidosis
DrugsEndoxan·Velcade·Bortezomib
Glaxosmithkline Research & Development Limited
Immune System Diseases
Italy, Greece, Spain
21/07/2026
Phase III
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to a Regimen of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination with Capsid Inhibitor Lenacapavir Twice Yearly in Virologically Suppressed Adults with HIV-1 Infection on Stable Oral Treatment Regimens
2025-524336-19-00HIV-1
DrugsCobicistat·Doravirine·Ritonavir·Tenofovir DF
Gilead Sciences Inc.
Virus Diseases
Poland, Italy, France, Spain, Germany, Netherlands
21/07/2026
Phase III
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to Long-acting Antiretroviral Therapy of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination With the Capsid Inhibitor Lenacapavir Twice-Yearly Versus Cabotegravir and Rilpivirine Every 8 Weeks in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy
2025-524335-39-00HIV-1
DrugsZinlirvimab·Rilpivirine·Cabotegravir·Lenacapavir
Gilead Sciences Inc.
Virus Diseases
Netherlands, Poland, Germany, France, Spain, Italy
21/07/2026
Phase III
A Phase 3, Double-blinded, Vehicle-controlled Trial to Investigate the Efficacy and Safety of Twice-daily Delgocitinib Cream in Adult Participants with Lichen Sclerosus During a 12-Week Initial Treatment Period Followed by a 40-Week Continuation Treatment Period
2025-524873-17-00Lichen Sclerosus
DrugDelgocitinib
Leo Pharma A/S
Skin and Connective Tissue Diseases
Italy, France, Spain, Poland, Germany
21/07/2026
Phase II
J2J-MC-JZLL - preEMBER: A Phase 2, Open-label Study Evaluating Imlunestrant in Premenopausal Women with Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
2025-523258-15-00Breast Neoplasms
DrugsGoserelin·Tamoxifen
Eli Lilly & Co.
Neoplasms
Belgium, France, Italy, Germany
21/07/2026
Phase II
DOXYCYCLINE PENETRATION INTO BONE AND JOINT.
2025-524744-36-00Patients requiring total hip arthroplasty for coxofemoral o…
DrugDoxycycline
Centre Hospitalier Universitaire De Caen Normandie
Bacterial Infections and Mycoses
France
20/07/2026
Phase I
Study of MX006 in Patients With Advanced and/or Metastatic Tumors known to express B7-H3
2025-524929-41-00Advanced Solid Tumor Types Known to Express B7-H3
Myricx Pharma Limited
Neoplasms
Spain
20/07/2026
Phase II
Randomized Phase II study of multi-peptide vaccination and bispecific PSMAxCD3 antibody treatment in patients with biochemical relapse of prostate cancer
2025-522144-41-00biochemical relapse of prostate cancer
Universitaetsklinikum Tuebingen AöR
Male Urogenital Diseases
Germany
20/07/2026
Phase II
HOVON 180 CLL: Prospective phase II trial of pirtobrutinib treatment (24 cycles) with 12 cycles of epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. ODYSSEUS study (Outcome-Driven trial for relapsed CLL/SLL combining BTK and bispecific antibodY to improve outcome)
2025-524842-89-00chronic lymphocytic leukemia (CLL) and small lymphocytic ly…
DrugsEpcoritamab·Pirtobrutinib
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
Neoplasms
Netherlands
20/07/2026
Phase II
A PHASE II, SINGLE ARM, OPEN LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF CEVOSTAMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED A PRIOR BCMA TARGETING CAR T-CELL THERAPY
2026-525736-42-00Multiple Myeloma (MM)
DrugsCevostamab·Pomalidomide·Dexamethasone
F. Hoffmann-La Roche AG
Neoplasms
Germany
20/07/2026
Phase II
A Phase IIb, randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy and safety of concomitant use of eplontersen and ALXN2220 compared with eplontersen and placebo in adult participants with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
2025-523908-75-00Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
DrugEplontersen
AstraZeneca AB
Cardiovascular Diseases
Germany, Italy, Spain, France, Sweden
20/07/2026
Phase III
A placebo-controlled comparability study to compare two presentations of cagrilintide for weight management in participants with overweight or obesity
2025-524249-29-00Participants with overweight or obesity
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Sweden, Greece, Hungary, Portugal
20/07/2026
Phase III
A randomized, placebo-controlled, double-blind Phase 3 study to evaluate the efficacy, safety and tolerability of votoplam in participants with Huntington’s Disease
2025-522227-99-00Huntington’s Disease
DrugVotoplam
Novartis Pharma AG
Nervous System Diseases
Norway, Poland, Spain, Sweden, Bulgaria, Netherlands, Finland, Portugal, Austria, Italy, Greece, Ireland, Czechia, France, Romania, Belgium, Germany, Denmark, Slovakia, Hungary
20/07/2026
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
2025-524711-36-00Narcolepsy Type 1
DrugALKS 2680
Alkermes Inc.
Nervous System Diseases
Sweden, Finland, Belgium, Spain, Austria, Netherlands, France, Norway, Germany, Italy, Poland
20/07/2026
Rows per page Showing 1–500 of 2557
1 2 3 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS). Derived from the EMA Clinical Trials Information System. Retrieved 6 October 2026. https://priyalifescience.com/clinical-trials-europe

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →

About this register

This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,561 trial records at the last sync on 06 Oct 2026, 03:17 UTC; this register shows the 2,557 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.

How many clinical trials does CTIS hold?

CTIS held 12,561 trial records at the last sync. Of the 2,557 most recently authorised trials shown in this register, 776 are Phase III. Trials are counted by authorisation, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.

Summary by phase

Trials by phase, 2,557 trials
PhaseTrialsShare
Phase III77630.3%
Phase II72828.5%
Phase I57322.4%
Phase IV26410.3%
Phase I/II2168.4%

Most active sponsors

Lead sponsors with the most trials
Lead sponsorTrials
AstraZeneca AB66
Merck Sharp & Dohme LLC50
Assistance Publique Hopitaux De Paris48
Pfizer Inc.48
Novartis Pharma AG43
Novo Nordisk A/S43
Bristol-Myers Squibb Services Unlimited Company38
Eli Lilly & Co.38
F. Hoffmann-La Roche AG38
Sanofi-Aventis Recherche & Developpement32

Member states with the most trials

Member states by number of trials with a site there
Member stateTrials
Spain1,059
France917
Germany897
Italy756
Poland605
Netherlands555
Belgium451
Czechia340
Denmark331
Hungary268

This register, in your inbox every Friday

One email a week with how many trials are recruiting in Ireland, new EMA and FDA approvals and medicine shortages, built from the same public registers as this page.

Free. Unsubscribe from any email with one click. See our privacy policy.

→

Browse trials by member state

Spain (1059) France (917) Germany (897) Italy (756) Poland (605) Netherlands (555) Belgium (451) Czechia (340) Denmark (331) Hungary (268) Greece (237) Austria (217) Romania (217) Sweden (216) Bulgaria (211)
→

Browse trials by condition

Advanced solid tumors (24) Atopic Dermatitis (19) Non-small Cell Lung Cancer (14) Obesity (14) Parkinson’s disease (14) Rheumatoid Arthritis (13) Ulcerative Colitis (12) Breast cancer (11) Major depressive disorder (11) Multiple sclerosis (11) Type 2 diabetes mellitus (10)
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.